Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 689 articles:
HTML format

Single Articles

    January 2021
  1. ATTIKU K, Bonney J, Agbosu E, Bonney E, et al
    Circulation of hepatitis delta virus and occult hepatitis B virus infection amongst HIV/HBV co-infected patients in Korle-Bu, Ghana.
    PLoS One. 2021;16:e0244507.
    PubMed     Abstract available

  2. SALYANI A, Shah J, Adam R, Otieno G, et al
    Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naive adults.
    PLoS One. 2021;16:e0244947.
    PubMed     Abstract available

  3. HEFFERNAN A, Ma Y, Nayagam S, Chan P, et al
    Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China.
    PLoS One. 2021;16:e0245288.
    PubMed     Abstract available

  4. HUANG YC, Huang CF, Liu SF, Liu HY, et al
    The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
    PLoS One. 2021;16:e0246376.
    PubMed     Abstract available

  5. Retraction: An Occult Hepatitis B-Derived Hepatoma Cell Line Carrying Persistent Nuclear Viral DNA and Permissive for Exogenous Hepatitis B Virus Infection.
    PLoS One. 2021;16:e0246549.

  6. KMUSH BL, Lu AM, Spillane T, Hruska B, et al
    Seroprevalence of hepatitis E virus antibodies in adults and children from upstate New York: A cross-sectional study.
    PLoS One. 2021;16:e0245850.
    PubMed     Abstract available

  7. LIN CP, Liang PC, Huang CI, Yeh ML, et al
    Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2021;16:e0245479.
    PubMed     Abstract available

  8. HASHIMOTO S, Shirasaki T, Yamashita T, Iwabuchi S, et al
    DOCK11 and DENND2A play pivotal roles in the maintenance of hepatitis B virus in host cells.
    PLoS One. 2021;16:e0246313.
    PubMed     Abstract available

  9. BAKER JD, Uhrich RL, Kraemer GC, Love JE, et al
    A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
    PLoS One. 2021;16:e0245962.
    PubMed     Abstract available

  10. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2021;16:e0245767.
    PubMed     Abstract available

  11. KWON JA, Chambers GM, Luciani F, Zhang L, et al
    Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
    PLoS One. 2021;16:e0245896.
    PubMed     Abstract available

  12. MAJD JABBARI S, Maajani K, Merat S, Poustchi H, et al
    An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
    PLoS One. 2021;16:e0246594.
    PubMed     Abstract available

  13. ANWAR WA, El Gaafary M, Girgis SA, Rafik M, et al
    Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt.
    PLoS One. 2021;16:e0246836.
    PubMed     Abstract available

  14. LEE DY, Chae SJ, Cho SR, Choi W, et al
    Nationwide seroprevalence of hepatitis A in South Korea from 2009 to 2019.
    PLoS One. 2021;16:e0245162.
    PubMed     Abstract available

  15. TESFA T, Hawulte B, Tolera A, Abate D, et al
    Hepatitis B virus infection and associated risk factors among medical students in eastern Ethiopia.
    PLoS One. 2021;16:e0247267.
    PubMed     Abstract available

  16. GRUBYTE S, Urboniene J, Nedzinskiene L, Jelinskaite A, et al
    Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.
    PLoS One. 2021;16:e0246704.
    PubMed     Abstract available

  17. MUHLBACHER AC, Sadler A
    Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
    PLoS One. 2021;16:e0245480.

  18. METWALLY AM, Elmosalami DM, Elhariri H, El Etreby LA, et al
    Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study.
    PLoS One. 2021;16:e0242257.
    PubMed     Abstract available

  19. CHARATCHAROENWITTHAYA P, Sukonrut K, Korpraphong P, Pongpaibul A, et al
    Diffusion-weighted magnetic resonance imaging for the assessment of liver fibrosis in chronic viral hepatitis.
    PLoS One. 2021;16:e0248024.
    PubMed     Abstract available

  20. HO H, Janjua NZ, McGrail KM, Harrison M, et al
    The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
    PLoS One. 2021;16:e0247843.
    PubMed     Abstract available

  21. RAJHI M, Haddad-Boubaker S, Chouikha A, Bourquain D, et al
    Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w).
    PLoS One. 2021;16:e0248249.
    PubMed     Abstract available

  22. DAN-NWAFOR CC, Adeoye I, Aderemi K, Onuoha M, et al
    Serological markers and risk factors associated with Hepatitis B virus infection among Federal Capital Territory prison inmates, Nigeria: Should we be concerned?
    PLoS One. 2021;16:e0248045.
    PubMed     Abstract available

  23. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
    A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
    PLoS One. 2021;16:e0247277.
    PubMed     Abstract available

  24. ATALAY AA, Abebe RK, Dadhi AE, Bededa WK, et al
    Seroprevalence of hepatitis B virus among pregnant women attending Antenatal care in Dilla University Referral Hospital Gedio Zone, Ethiopia; health facility based cross-sectional study.
    PLoS One. 2021;16:e0249216.
    PubMed     Abstract available

  25. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
    Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PLoS One. 2021;16:e0248748.
    PubMed     Abstract available

  26. HERNANDEZ CJ, Trujillo D, Sicro S, Meza J, et al
    High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.
    PLoS One. 2021;16:e0249219.
    PubMed     Abstract available

  27. TONEN-WOLYEC S, Djang'eing'a RM, Batina-Agasa S, Kayembe Tshilumba C, et al
    Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.
    PLoS One. 2021;16:e0249701.
    PubMed     Abstract available

  28. Correction: Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2021;16:e0250185.
    PubMed     Abstract available

  29. MIRZAZADEH A, Chen YH, Lin J, Burk K, et al
    Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
    PLoS One. 2021;16:e0249585.
    PubMed     Abstract available

  30. KASHIWAKURA JI, Saitoh K, Ihara T, Sasaki Y, et al
    Correction: Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells.
    PLoS One. 2021;16:e0250536.
    PubMed     Abstract available

  31. AHMED HR, Waly NGFM, Abd El-Baky RM, Yahia R, et al
    Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    PLoS One. 2021;16:e0249770.
    PubMed     Abstract available

  32. PONNUVEL S, Fletcher GJ, Anantharam R, Varughese S, et al
    Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
    PLoS One. 2021;16:e0250263.
    PubMed     Abstract available

  33. PALAYEW A, Schmidt AM, Saeed S, Cooper CL, et al
    Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada.
    PLoS One. 2021;16:e0249836.
    PubMed     Abstract available

  34. ANTENEH ZA, Wondaye E, Mengesha EW
    Hepatitis B virus infection and its determinants among HIV positive pregnant women: Multicenter unmatched case-control study.
    PLoS One. 2021;16:e0251084.
    PubMed     Abstract available

  35. VIEIRA BARBOSA J, Sahli R, Aubert V, Chaouch A, et al
    Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
    PLoS One. 2021;16:e0250347.
    PubMed     Abstract available

  36. KAARTINEN K, Vuoti S, Honkanen E, Loyttyniemi E, et al
    Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.
    PLoS One. 2021;16:e0251392.
    PubMed     Abstract available

  37. Correction: Correction: Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2021;16:e0251539.
    PubMed     Abstract available

  38. LEE CY, Wu PH, Lu MW, Chen TC, et al
    High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.
    PLoS One. 2021;16:e0251158.
    PubMed     Abstract available

  39. BUGGISCH P, Heiken H, Mauss S, Weber B, et al
    Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
    PLoS One. 2021;16:e0250833.
    PubMed     Abstract available

  40. CHA HJ, Hwang J, Lee LE, Park Y, et al
    The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease.
    PLoS One. 2021;16:e0244950.
    PubMed     Abstract available

  41. IREKEOLA AA, Malek NA, Wada Y, Mustaffa N, et al
    Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251673.
    PubMed     Abstract available

  42. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    PubMed     Abstract available

  43. DIDIYA R, Gyenwali D, Pokhrel TN, Devkota S, et al
    Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
    PLoS One. 2021;16:e0252490.
    PubMed     Abstract available

  44. MALAMBA SS, Muyinda H, Ogwang DM, Katamba A, et al
    Cango Lyec (Healing the Elephant): Chronic Hepatitis B Virus among post-conflict affected populations living in mid-Northern Uganda.
    PLoS One. 2021;16:e0251573.
    PubMed     Abstract available

  45. WURCEL AG, Reyes J, Zubiago J, Koutoujian PJ, et al
    "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
    PLoS One. 2021;16:e0250901.
    PubMed     Abstract available

  46. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    PubMed     Abstract available

  47. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    PubMed     Abstract available

  48. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    PubMed     Abstract available

  49. GAHRTON C, Hakansson A, Kaberg M, Jerkeman A, et al
    Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
    PLoS One. 2021;16:e0253710.
    PubMed     Abstract available

  50. RASTOGI A, Chauhan S, Ramalingam A, Verma M, et al
    Capacity building of healthcare workers: Key step towards elimination of viral hepatitis in developing countries.
    PLoS One. 2021;16:e0253539.
    PubMed     Abstract available

  51. TORO DM, Ramasawmy R, Silva Neto PV, Pereira GL, et al
    Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil.
    PLoS One. 2021;16:e0253470.
    PubMed     Abstract available

  52. RAHMAN S, Wathington D, Waterboer T, Pawlita M, et al
    Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.
    PLoS One. 2021;16:e0253005.
    PubMed     Abstract available

  53. ADANE T, Getawa S
    The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251570.
    PubMed     Abstract available

  54. LIU HY, Lin YH, Lin PJ, Tsai PC, et al
    Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
    PLoS One. 2021;16:e0254028.
    PubMed     Abstract available

  55. GOMES LC, Sanson MCG, Brainin P, de Melo MDCV, et al
    Levels of hepatitis B antibody titers are affected by age and doses gap time in children from a high endemic area of the western Amazon.
    PLoS One. 2021;16:e0253752.
    PubMed     Abstract available

  56. LLORENS-REVULL M, Costafreda MI, Rico A, Guerrero-Murillo M, et al
    Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    PLoS One. 2021;16:e0254243.
    PubMed     Abstract available

  57. HOA TN, Munshi SU, Ngoc KN, Ngoc CL, et al
    A tightly clustered hepatitis E virus genotype 1a is associated with endemic and outbreak infections in Bangladesh.
    PLoS One. 2021;16:e0255054.
    PubMed     Abstract available

  58. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    PubMed     Abstract available

    January 2020
  59. RIVERO-JUAREZ A, Guijo-Rubio D, Tellez F, Palacios R, et al
    Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals.
    PLoS One. 2020;15:e0227188.
    PubMed     Abstract available

  60. HAMDI M, Abdel-Bar HM, Elmowafy E, Al-Jamal KT, et al
    An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect.
    PLoS One. 2020;15:e0227231.
    PubMed     Abstract available

  61. TSAI WL, Wang CF, Cheng JS, Chen WC, et al
    Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience.
    PLoS One. 2020;15:e0227424.
    PubMed     Abstract available

  62. SHAO LN, Zhang ST, Wang N, Yu WJ, et al
    Platelet indices significantly correlate with liver fibrosis in HCV-infected patients.
    PLoS One. 2020;15:e0227544.
    PubMed     Abstract available

  63. WEITZEL T, Rodriguez F, Noriega LM, Marcotti A, et al
    Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: A cross-sectional serosurvey.
    PLoS One. 2020;15:e0227776.
    PubMed     Abstract available

  64. GOOD SS, Moussa A, Zhou XJ, Pietropaolo K, et al
    Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.
    PLoS One. 2020;15:e0227104.
    PubMed     Abstract available

  65. NUTINI MFR, Hunter J, Giron L, Pires AFNPC, et al
    HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country.
    PLoS One. 2020;15:e0227082.
    PubMed     Abstract available

  66. LIU GY, Tang O, Brotman DJ, Miller ER 3rd, et al
    Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy.
    PLoS One. 2020;15:e0224977.
    PubMed     Abstract available

  67. FU B, Ji Y, Hu S, Ren T, et al
    Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis.
    PLoS One. 2020;15:e0227532.
    PubMed     Abstract available

  68. VINIKOOR MJ, Sinkala E, Kanunga A, Muchimba M, et al
    Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia.
    PLoS One. 2020;15:e0227041.
    PubMed     Abstract available

  69. HUHN GD, Ramgopal M, Jain MK, Hinestrosa F, et al
    HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PLoS One. 2020;15:e0224875.
    PubMed     Abstract available

  70. SAINE ME, Moore TM, Szymczak JE, Bamford LP, et al
    Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection.
    PLoS One. 2020;15:e0228471.
    PubMed     Abstract available

  71. PATEL SV, Jayaweera DT, Althoff KN, Eron JJ, et al
    Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
    PLoS One. 2020;15:e0228847.
    PubMed     Abstract available

  72. WAN YM, Li ZQ, Liu C, He YF, et al
    Mesenchymal stem cells reduce alcoholic hepatitis in mice via suppression of hepatic neutrophil and macrophage infiltration, and of oxidative stress.
    PLoS One. 2020;15:e0228889.
    PubMed     Abstract available

  73. LEE KS, Quintiliani L, Heinz A, Johnson NL, et al
    A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
    PLoS One. 2020;15:e0228767.
    PubMed     Abstract available

  74. CARVALHO-GOMES A, Cubells A, Pallares C, Hontangas V, et al
    A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.
    PLoS One. 2020;15:e0228351.
    PubMed     Abstract available

  75. MODIYINJI AF, Sanding GMAM, Atsama MA, Monamele CG, et al
    Serological and molecular investigation of hepatitis E virus in pigs reservoirs from Cameroon reveals elevated seroprevalence and presence of genotype 3.
    PLoS One. 2020;15:e0229073.
    PubMed     Abstract available

  76. SIRINAWASATIEN A, Techasirioangkun T
    Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PLoS One. 2020;15:e0229517.
    PubMed     Abstract available

  77. CASTRO R, Perazzo H, de Araujo LAMM, Gutierres IG, et al
    Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis.
    PLoS One. 2020;15:e0229143.
    PubMed     Abstract available

  78. LIN SF, Tung SY, Wei KL, Chen CH, et al
    Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
    PLoS One. 2020;15:e0229994.
    PubMed     Abstract available

  79. ZHAO Y, Chen YL, Song HQ, Huang PY, et al
    Effects of maternal hepatitis B surface antigen positive status on the pregnancy outcomes: A retrospective study in Xiamen, China, 2011-2018.
    PLoS One. 2020;15:e0229732.
    PubMed     Abstract available

  80. SCHMIDBAUER C, Schubert R, Schutz A, Schwanke C, et al
    Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
    PLoS One. 2020;15:e0229239.
    PubMed     Abstract available

  81. STEFFEN G, Sperle I, Leendertz SA, Sarma N, et al
    The epidemiology of Hepatitis B, C and D in Germany: A scoping review.
    PLoS One. 2020;15:e0229166.
    PubMed     Abstract available

  82. MARCELLIN P, Xie Q, Woon Paik S, Flisiak R, et al
    Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
    PLoS One. 2020;15:e0230893.
    PubMed     Abstract available

  83. KHAN HU, Khan S, Shah MA, Attaullah S, et al
    Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naive HCV positive Pakistani patients.
    PLoS One. 2020;15:e0231480.
    PubMed     Abstract available

  84. DOMINGUEZ-RODRIGUEZ S, Prieto L, Fernandez McPhee C, Illan-Ramos M, et al
    Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain.
    PLoS One. 2020;15:e0230109.
    PubMed     Abstract available

  85. PAZGAN-SIMON M, Kukla M, Zuwala-Jagiello J, Derra A, et al
    Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
    PLoS One. 2020;15:e0227459.
    PubMed     Abstract available

  86. PRINSENBERG T, Rebers S, Boyd A, Zuure F, et al
    Dried blood spot self-sampling at home is a feasible technique for hepatitis C RNA detection.
    PLoS One. 2020;15:e0231385.
    PubMed     Abstract available

  87. CHIU SM, Tsai MC, Lin CY, Chen CH, et al
    Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment.
    PLoS One. 2020;15:e0231102.
    PubMed     Abstract available

  88. KRACHT PAM, Arends JE, Hoepelman AIM, Vervoort SCJM, et al
    The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study.
    PLoS One. 2020;15:e0230756.
    PubMed     Abstract available

  89. PRATEDRAT P, Chuaypen N, Nimsamer P, Payungporn S, et al
    Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma.
    PLoS One. 2020;15:e0232211.
    PubMed     Abstract available

  90. DORTEY BA, Anaba EA, Lassey AT, Damale NKR, et al
    Seroprevalence of Hepatitis B virus infection and associated factors among pregnant women at Korle-Bu Teaching Hospital, Ghana.
    PLoS One. 2020;15:e0232208.
    PubMed     Abstract available

  91. ADAM A, Fusheini A
    Knowledge, risk of infection, and vaccination status of hepatitis B virus among rural high school students in Nanumba North and South Districts of Ghana.
    PLoS One. 2020;15:e0231930.
    PubMed     Abstract available

  92. WAKE T, Tateishi R, Fukumoto T, Nakagomi R, et al
    Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
    PLoS One. 2020;15:e0231836.
    PubMed     Abstract available

  93. RAMDASI AY, Arankalle VA
    The expression patterns of immune response genes in the Peripheral Blood Mononuclear cells of pregnant women presenting with subclinical or clinical HEV infection are different and trimester-dependent: A whole transcriptome analysis.
    PLoS One. 2020;15:e0228068.
    PubMed     Abstract available

  94. WON YK, Kang KS, Gonzalez YS, Razavi H, et al
    A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    PLoS One. 2020;15:e0232186.
    PubMed     Abstract available

  95. HOSKING K, Stewart G, Mobsby M, Skov S, et al
    Data linkage and computerised algorithmic coding to enhance individual clinical care for Aboriginal people living with chronic hepatitis B in the Northern Territory of Australia - Is it feasible?
    PLoS One. 2020;15:e0232207.
    PubMed     Abstract available

  96. BANCHA B, Kinfe AA, Chanko KP, Workie SB, et al
    Prevalence of hepatitis B viruses and associated factors among pregnant women attending antenatal clinics in public hospitals of Wolaita Zone, South Ethiopia.
    PLoS One. 2020;15:e0232653.
    PubMed     Abstract available

  97. PIECHA F, Ganssler JM, Ozga AK, Wehmeyer MH, et al
    Treatment and re-treatment results of HCV patients in the DAA era.
    PLoS One. 2020;15:e0232773.
    PubMed     Abstract available

  98. PHILIP G, Djerboua M, Carlone D, Flemming JA, et al
    Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data.
    PLoS One. 2020;15:e0229218.
    PubMed     Abstract available

  99. AKHTAR S, Nasir JA, Usman M, Sarwar A, et al
    The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0232931.
    PubMed     Abstract available

  100. RUIZ-EXTREMERA A, Diaz-Alcazar MDM, Munoz-Gamez JA, Cabrera-Lafuente M, et al
    Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission.
    PLoS One. 2020;15:e0233528.
    PubMed     Abstract available

  101. NGUYEN DT, Tran TTT, Nghiem NM, Le PT, et al
    Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    PLoS One. 2020;15:e0233446.
    PubMed     Abstract available

  102. POILIL SURENDRAN S, George Thomas R, Moon MJ, Park R, et al
    Effect of hepato-toxins in the acceleration of hepatic fibrosis in hepatitis B mice.
    PLoS One. 2020;15:e0232619.
    PubMed     Abstract available

  103. ISMAIL MB, Al Kassaa I, El Safadi D, Al Omari S, et al
    Prevalence of anti-hepatitis E virus IgG antibodies in sera from hemodialysis patients in Tripoli, Lebanon.
    PLoS One. 2020;15:e0233256.
    PubMed     Abstract available

  104. JEPKEMEI KB, Ochwoto M, Swidinsky K, Day J, et al
    Characterization of occult hepatitis B in high-risk populations in Kenya.
    PLoS One. 2020;15:e0233727.
    PubMed     Abstract available

  105. HE L, Yuan H, Liang J, Hong J, et al
    Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.
    PLoS One. 2020;15:e0233702.
    PubMed     Abstract available

  106. LIN WC, Lin YS, Chang CW, Chang CW, et al
    Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.
    PLoS One. 2020;15:e0233212.
    PubMed     Abstract available

  107. ABESIG J, Chen Y, Wang H, Sompo FM, et al
    Prevalence of viral hepatitis B in Ghana between 2015 and 2019: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0234348.
    PubMed     Abstract available

  108. MORISHITA N, Sakamori R, Yamada T, Kai Y, et al
    Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    PLoS One. 2020;15:e0234811.
    PubMed     Abstract available

  109. CABEZAS C, Trujillo O, Gonzales-Vivanco A, Benites Villafane CM, et al
    Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2020;15:e0234273.
    PubMed     Abstract available

  110. DURACINSKY M, Thonon F, Bun S, Ben Nasr I, et al
    Good acceptability of HIV, HBV, and HCV screening during immigration medical check-up amongst migrants in France in the STRADA study.
    PLoS One. 2020;15:e0235260.
    PubMed     Abstract available

  111. Retraction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2020;15:e0235375.

  112. ZHENG Y, Zhang L, Zhu X, Guo G, et al
    A comparative study of two methods to predict the incidence of hepatitis B in Guangxi, China.
    PLoS One. 2020;15:e0234660.
    PubMed     Abstract available

  113. TENG CF, Tsai HW, Li TC, Wang T, et al
    Detection of hepatitis B virus pre-S mutants in plasma by a next-generation sequencing-based platform determines their patterns in liver tissues.
    PLoS One. 2020;15:e0234773.
    PubMed     Abstract available

  114. BRAIN D, Mitchell J, O'Beirne J
    Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care.
    PLoS One. 2020;15:e0234577.
    PubMed     Abstract available

    Epidemiology of hepatitis B and C virus infections among patients who booked for surgical procedures at Felegehiwot referral hospital, Northwest Ethiopia.
    PLoS One. 2020;15:e0234822.
    PubMed     Abstract available

  116. LEE MH, Lee GA, Lee SH, Park YH, et al
    A systematic review on the causes of the transmission and control measures of outbreaks in long-term care facilities: Back to basics of infection control.
    PLoS One. 2020;15:e0229911.
    PubMed     Abstract available

  117. TRAEGER MW, Pedrana AE, van Santen DK, Doyle JS, et al
    The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
    PLoS One. 2020;15:e0235445.
    PubMed     Abstract available

  118. ZHANG Y, Gao Z, Wang S, Liu J, et al
    Hepatitis C virus genotype/subtype distribution and evolution among Chinese blood donors: Revealing recent viral expansion.
    PLoS One. 2020;15:e0235612.
    PubMed     Abstract available

  119. COPPOCK D, Chou E, Gracely E, Gross R, et al
    Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics.
    PLoS One. 2020;15:e0235778.
    PubMed     Abstract available

  120. SSEKAMATTE T, Mukama T, Kibira SPS, Ndejjo R, et al
    Hepatitis B screening and vaccination status of healthcare providers in Wakiso district, Uganda.
    PLoS One. 2020;15:e0235470.
    PubMed     Abstract available

  121. TRONINA O, Gotlib J, Malkowski P, Jaworski M, et al
    Translation and validation study of the Polish version of the Brief Hepatitis C Knowledge Scale.
    PLoS One. 2020;15:e0235764.
    PubMed     Abstract available

  122. JARGALSAIKHAN G, Eichner M, Boldbaatar D, Bat-Ulzii P, et al
    Sensitivity and specificity of commercially available rapid diagnostic tests for viral hepatitis B and C screening in serum samples.
    PLoS One. 2020;15:e0235036.
    PubMed     Abstract available

  123. LI H, Marks KM, Talal AH, van Seggelen WO, et al
    Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing.
    PLoS One. 2020;15:e0235237.
    PubMed     Abstract available

  124. SALINES M, Andraud M, Rose N, Widgren S, et al
    A between-herd data-driven stochastic model to explore the spatio-temporal spread of hepatitis E virus in the French pig production network.
    PLoS One. 2020;15:e0230257.
    PubMed     Abstract available

  125. TRAN HTL, Morikawa K, Anggakusuma, Zibi R, et al
    OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease.
    PLoS One. 2020;15:e0236447.
    PubMed     Abstract available

  126. PEREIRA FM, Almeida MDCC, Santos FLN, Carreiro RP, et al
    Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil.
    PLoS One. 2020;15:e0223087.
    PubMed     Abstract available

  127. BERG MG, Olivo A, Forberg K, Harris BJ, et al
    Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses.
    PLoS One. 2020;15:e0236046.
    PubMed     Abstract available

  128. SHAWON MA, Yousuf MAK, Raheem E, Ahmed S, et al
    Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh.
    PLoS One. 2020;15:e0232121.
    PubMed     Abstract available

  129. PALAYEW A, Stumo SR, Cooke GS, Hutchinson SJ, et al
    The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    PLoS One. 2020;15:e0235715.
    PubMed     Abstract available

  130. KOC OM, Kremer C, Hens N, Bielen R, et al
    Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium.
    PLoS One. 2020;15:e0234740.
    PubMed     Abstract available

  131. VERSTER AM, Liang JE, Rostal MK, Kemp A, et al
    Selected wetland soil properties correlate to Rift Valley fever livestock mortalities reported in 2009-10 in central South Africa.
    PLoS One. 2020;15:e0232481.
    PubMed     Abstract available

  132. CABEZAS C, Trujillo O, Balbuena J, Peceros FM, et al
    Decrease in the prevalence of hepatitis B and D virus infections in an endemic area in Peru 23 years after the introduction of the first pilot vaccination program against hepatitis B.
    PLoS One. 2020;15:e0236993.
    PubMed     Abstract available

  133. NGWAGA T, Kong L, Lin D, Schoborg C, et al
    Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    PLoS One. 2020;15:e0237162.
    PubMed     Abstract available

  134. JEONG GU, Ahn BY, Jung J, Kim H, et al
    A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants.
    PLoS One. 2020;15:e0236704.
    PubMed     Abstract available

  135. TABU K, Mawatari S, Oda K, Kumagai K, et al
    Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    PLoS One. 2020;15:e0237475.
    PubMed     Abstract available

  136. YEN HH, Su PY, Zeng YH, Liu IL, et al
    Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
    PLoS One. 2020;15:e0237582.
    PubMed     Abstract available

  137. YU HC, Lin KH, Tsay FW, Tsai TJ, et al
    Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies.
    PLoS One. 2020;15:e0237586.
    PubMed     Abstract available

  138. DE VILLIERS MJ, Gamkrelidze I, Hallett TB, Nayagam S, et al
    Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models.
    PLoS One. 2020;15:e0237525.
    PubMed     Abstract available

  139. BARUTI K, Lentz K, Anderson M, Ajibola G, et al
    Hepatitis B virus prevalence and vaccine antibody titers in children HIV exposed but uninfected in Botswana.
    PLoS One. 2020;15:e0237252.
    PubMed     Abstract available

  140. BOBARDT M, Hansson MJ, Mayo P, Ure D, et al
    Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.
    PLoS One. 2020;15:e0237236.
    PubMed     Abstract available

  141. FAGUNDES RN, Ferreira LEVVC, Pace FHL
    Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
    PLoS One. 2020;15:e0237005.
    PubMed     Abstract available

  142. MINOSSE C, Messina F, Garbuglia AR, Meschi S, et al
    Origin of HAV strains responsible for 2016-2017 outbreak among MSM: Viral phylodynamics in Lazio region.
    PLoS One. 2020;15:e0234010.
    PubMed     Abstract available

  143. ASHHAB AA, Rodin H, Campos M, Abu-Sulb A, et al
    Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection.
    PLoS One. 2020;15:e0237398.
    PubMed     Abstract available

  144. DUCHESNE L, Hejblum G, Njouom R, Toure Kane C, et al
    Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa.
    PLoS One. 2020;15:e0238035.
    PubMed     Abstract available

  145. WALDENSTROM J, Nystrom K, Nilsson S, Norkrans G, et al
    The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
    PLoS One. 2020;15:e0237840.
    PubMed     Abstract available

  146. ANDERSON ES, Russell C, Basham K, Montgomery M, et al
    High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department.
    PLoS One. 2020;15:e0233927.
    PubMed     Abstract available

  147. HANSON J, Fox M, Anderson A, Fox P, et al
    Chronic hepatitis B in remote, tropical Australia; successes and challenges.
    PLoS One. 2020;15:e0238719.
    PubMed     Abstract available

  148. NIELSEN S, Hansen JF, Hay G, Cowan S, et al
    Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers.
    PLoS One. 2020;15:e0238203.
    PubMed     Abstract available

  149. CHOI YH, Zhang X, Srinivasamoorthy G, Purdy MA, et al
    Transcriptome analysis in rhesus macaques infected with hepatitis E virus genotype 1/3 infections and genotype 1 re-infection.
    PLoS One. 2020;15:e0237618.
    PubMed     Abstract available

  150. READY E, Habecker P, Abadie R, Khan B, et al
    Competing forces of withdrawal and disease avoidance in the risk networks of people who inject drugs.
    PLoS One. 2020;15:e0235124.
    PubMed     Abstract available

  151. LIU L, Hou J, Xu Y, Qin L, et al
    PD-L1 upregulation by IFN-alpha/gamma-mediated Stat1 suppresses anti-HBV T cell response.
    PLoS One. 2020;15:e0228302.
    PubMed     Abstract available

  152. LI J, Abosmaha E, Coffin CS, Labonte P, et al
    Reticulon-3 modulates the incorporation of replication competent hepatitis C virus molecules for release inside infectious exosomes.
    PLoS One. 2020;15:e0239153.
    PubMed     Abstract available

  153. GUO Y, Feng Y, Qu F, Zhang L, et al
    Prediction of hepatitis E using machine learning models.
    PLoS One. 2020;15:e0237750.
    PubMed     Abstract available

  154. ADEYEMI OA, Itanyi IU, Ozigbu CE, Stadnick N, et al
    Sero-prevalence and determinants of Hepatitis B among a cohort of HIV-infected women of reproductive age in Nigeria.
    PLoS One. 2020;15:e0236456.
    PubMed     Abstract available

  155. TAMANDJOU TCHUEM CR, Brandt L, Nel ER, Cotton MF, et al
    Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.
    PLoS One. 2020;15:e0238839.
    PubMed     Abstract available

  156. CARDONA-ARIAS JA, Correa JCC, Higuita-Gutierrez LF
    Prevalence of hepatitis B/C viruses and associated factors in key groups attending a health services institution in Colombia, 2019.
    PLoS One. 2020;15:e0238655.
    PubMed     Abstract available

    Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
    PLoS One. 2020;15:e0236543.
    PubMed     Abstract available

  158. INGASIA LAO, Kostaki EG, Paraskevis D, Kramvis A, et al
    Global and regional dispersal patterns of hepatitis B virus genotype E from and in Africa: A full-genome molecular analysis.
    PLoS One. 2020;15:e0240375.
    PubMed     Abstract available

  159. HOFFMANN P, Behnisch R, Gsenger J, Schnitzler P, et al
    Hepatitis E seroprevalence in a German cohort of patients with inflammatory bowel diseases.
    PLoS One. 2020;15:e0239825.
    PubMed     Abstract available

  160. THOMSEN H, Li X, Sundquist K, Sundquist J, et al
    Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases.
    PLoS One. 2020;15:e0240794.
    PubMed     Abstract available

  161. BAYU H, Elias B, Abdisa S, Tune A, et al
    Post exposure prophylaxis coverage, vertical transmission and associated factors among hepatitis B exposed newborns delivered at Arsi zone health institutions, 2019.
    PLoS One. 2020;15:e0238987.
    PubMed     Abstract available

  162. AN J, Kim HI, Chang S, Shim JH, et al
    Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma.
    PLoS One. 2020;15:e0238078.
    PubMed     Abstract available

  163. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
    Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
    PLoS One. 2020;15:e0241199.
    PubMed     Abstract available

  164. ABDELLA S, Moshago Berheto T, Tolera G, Belete W, et al
    Sero-prevalence of transfusion transmittable infections: HIV, Hepatitis B, C and Treponema pallidum and associated factors among blood donors in Ethiopia: A retrospective study.
    PLoS One. 2020;15:e0241086.
    PubMed     Abstract available

  165. AWOKE N, Mulgeta H, Lolaso T, Tekalign T, et al
    Full-dose hepatitis B virus vaccination coverage and associated factors among health care workers in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0241226.
    PubMed     Abstract available

  166. GALLACH M, Vergara M, Pedro da Costa J, Miquel M, et al
    Correction: Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2020;15:e0241559.
    PubMed     Abstract available

  167. HAGA H, Sato H, Koseki A, Saito T, et al
    A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus.
    PLoS One. 2020;15:e0242028.
    PubMed     Abstract available

  168. ABE K, Fujita M, Hayashi M, Takahashi A, et al
    Association of serum 25-hydroxyvitamin D levels with severe necroinflammatory activity and inflammatory cytokine production in type I autoimmune hepatitis.
    PLoS One. 2020;15:e0239481.
    PubMed     Abstract available

  169. JAVANBAKHT M, Archer R, Klausner J
    Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.
    PLoS One. 2020;15:e0241615.
    PubMed     Abstract available

  170. SEMMO N, Mullhaupt B, Ruckstuhl L, Magenta L, et al
    A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naive patients suffering from fatigue and receiving 3D regimen: The HEMATITE study.
    PLoS One. 2020;15:e0241267.
    PubMed     Abstract available

  171. KASHIWAKURA JI, Saitoh K, Ihara T, Sasaki Y, et al
    Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells.
    PLoS One. 2020;15:e0241440.
    PubMed     Abstract available

  172. GEZAHEGN LK, Argaw E, Assefa B, Geberesilassie A, et al
    Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study.
    PLoS One. 2020;15:e0241346.
    PubMed     Abstract available

  173. PEREZ-RAMIREZ E, Cano-Gomez C, Llorente F, Adzic B, et al
    External quality assessment of Rift Valley fever diagnosis in 17 veterinary laboratories of the Mediterranean and Black Sea regions.
    PLoS One. 2020;15:e0239478.
    PubMed     Abstract available

  174. AIYAMA T, Orimo T, Yokoo H, Ohata T, et al
    Adenomatous polyposis coli-binding protein end-binding 1 promotes hepatocellular carcinoma growth and metastasis.
    PLoS One. 2020;15:e0239462.
    PubMed     Abstract available

  175. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
    The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
    PLoS One. 2020;15:e0242601.
    PubMed     Abstract available

  176. PATEL NH, Meier-Stephenson V, Genetu M, Damtie D, et al
    Prevalence and genetic variability of occult hepatitis B virus in a human immunodeficiency virus positive patient cohort in Gondar, Ethiopia.
    PLoS One. 2020;15:e0242577.
    PubMed     Abstract available

  177. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
    Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
    PLoS One. 2020;15:e0242101.
    PubMed     Abstract available

  178. CHIESA A, Ochola E, Oreni L, Vassalini P, et al
    Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?
    PLoS One. 2020;15:e0242278.
    PubMed     Abstract available

  179. JIANG K, Mohammad MK, Dar WA, Kong J, et al
    Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
    PLoS One. 2020;15:e0239624.
    PubMed     Abstract available

  180. TENG CF, Li TC, Huang HY, Chan WL, et al
    Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection.
    PLoS One. 2020;15:e0242748.
    PubMed     Abstract available

  181. SHRESTHA DB, Khadka M, Khadka M, Subedi P, et al
    Hepatitis B vaccination status and knowledge, attitude, and practice regarding Hepatitis B among preclinical medical students of a medical college in Nepal.
    PLoS One. 2020;15:e0242658.
    PubMed     Abstract available

  182. PATIL S, Rao A, Pathak P, Kurle S, et al
    Unsterile injection equipment associated with HIV outbreak and an extremely high prevalence of HCV-A case-control investigation from Unnao, India.
    PLoS One. 2020;15:e0243534.
    PubMed     Abstract available

  183. VETTER BN, Ongarello S, Tyshkovskiy A, Alkhazashvili M, et al
    Sensitivity and specificity of rapid hepatitis C antibody assays in freshly collected whole blood, plasma and serum samples: A multicentre prospective study.
    PLoS One. 2020;15:e0243040.
    PubMed     Abstract available

  184. AKIYAMA MJ, Ross J, Rimawi F, Fox A, et al
    Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study.
    PLoS One. 2020;15:e0242623.
    PubMed     Abstract available

  185. SAZZAD HMS, McCredie L, Treloar C, Lloyd AR, et al
    Violence and hepatitis C transmission in prison-A modified social ecological model.
    PLoS One. 2020;15:e0243106.
    PubMed     Abstract available

  186. MANATHUNGE A, Barbaric J, Mestrovic T, Beneragama S, et al
    HIV prevalence, sexual risk behaviours and HIV testing among female sex workers in three cities in Sri Lanka: Findings from respondent-driven sampling surveys.
    PLoS One. 2020;15:e0239951.
    PubMed     Abstract available

  187. DUMAIDI K, Qaraqe H, Al-Jawabreh A, Abu-Helu R, et al
    Genetic diversity, haplotype analysis, and risk factor assessment of hepatitis A virus isolates from the West Bank, Palestine during the period between 2014 and 2016.
    PLoS One. 2020;15:e0240339.
    PubMed     Abstract available

  188. LAWAL MA, Adeniyi OF, Akintan PE, Salako AO, et al
    Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.
    PLoS One. 2020;15:e0243656.
    PubMed     Abstract available

  189. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
    Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    PLoS One. 2020;15:e0243725.
    PubMed     Abstract available

  190. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
    Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
    PLoS One. 2020;15:e0243473.
    PubMed     Abstract available

  191. BEKKI S, Hashimoto S, Yamasaki K, Komori A, et al
    Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0241002.
    PubMed     Abstract available

  192. MIGITA K, Nakamura M, Aiba Y, Kozuru H, et al
    Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis.
    PLoS One. 2020;15:e0238540.
    PubMed     Abstract available

  193. PEARCE ME, Yu A, Alvarez M, Bartlett SR, et al
    Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019.
    PLoS One. 2020;15:e0244575.
    PubMed     Abstract available

  194. KHLAIPHUENGSIN A, Chuaypen N, Sodsai P, Reantragoon R, et al
    Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
    PLoS One. 2020;15:e0244112.
    PubMed     Abstract available

  195. AFAA TJ, Amegan-Aho KH, Dono MT, Odei E, et al
    Clinical characteristics of paediatric autoimmune hepatitis at a referral hospital in Sub Saharan Africa.
    PLoS One. 2020;15:e0239964.
    PubMed     Abstract available

  196. TUCKER CJ, Melocik KA, Anyamba A, Linthicum KJ, et al
    Reanalysis of the 2000 Rift Valley fever outbreak in Southwestern Arabia.
    PLoS One. 2020;15:e0233279.
    PubMed     Abstract available

  197. HEFELE L, Syphan S, Xayavong D, Homsana A, et al
    Timeliness of immunisation with the pentavalent vaccine at different levels of the health care system in the Lao People's Democratic Republic: A cross-sectional study.
    PLoS One. 2020;15:e0242502.
    PubMed     Abstract available

  198. POURCHER V, Gourmelen J, Bureau I, Bouee S, et al
    Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France.
    PLoS One. 2020;15:e0243529.
    PubMed     Abstract available

    January 2019
  199. FOSTER GR, Asselah T, Kopecky-Bromberg S, Lei Y, et al
    Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
    PLoS One. 2019;14:e0208506.
    PubMed     Abstract available

  200. POPPING S, Hullegie SJ, Boerekamps A, Rijnders BJA, et al
    Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.
    PLoS One. 2019;14:e0210179.
    PubMed     Abstract available

  201. YEN YH, Kee KM, Chen CH, Hu TH, et al
    Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
    PLoS One. 2019;14:e0208858.
    PubMed     Abstract available

  202. BRENNER N, Mentzer AJ, Butt J, Braband KL, et al
    Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
    PLoS One. 2019;14:e0210407.
    PubMed     Abstract available

  203. KONERMAN MA, Beste LA, Van T, Liu B, et al
    Machine learning models to predict disease progression among veterans with hepatitis C virus.
    PLoS One. 2019;14:e0208141.
    PubMed     Abstract available

  204. SHTEYER E, Shekhtman L, Zinger T, Harari S, et al
    Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.
    PLoS One. 2019;14:e0210173.
    PubMed     Abstract available

  205. MANE A, Sacks J, Sharma S, Singh H, et al
    Evaluation of five rapid diagnostic tests for detection of antibodies to hepatitis C virus (HCV): A step towards scale-up of HCV screening efforts in India.
    PLoS One. 2019;14:e0210556.
    PubMed     Abstract available

  206. XIAO Y, Shen M, Ma S, Wen SW, et al
    The association between inter-twin birth weight discordance and hepatitis C: The United States 2011-2015 twin birth registration data.
    PLoS One. 2019;14:e0211683.
    PubMed     Abstract available

  207. SHILI-MASMOUDI S, Sogni P, de Ledinghen V, Esterle L, et al
    Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
    PLoS One. 2019;14:e0211286.
    PubMed     Abstract available

  208. SHTEYER E, Shekhtman L, Zinger T, Harari S, et al
    Correction: Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.
    PLoS One. 2019;14:e0212252.
    PubMed     Abstract available

  209. SHENGE JA, Odaibo GN, Olaleye DO
    Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0210724.
    PubMed     Abstract available

  210. ANABIRE NG, Aryee PA, Abdul-Karim A, Abdulai IB, et al
    Prevalence of malaria and hepatitis B among pregnant women in Northern Ghana: Comparing RDTs with PCR.
    PLoS One. 2019;14:e0210365.
    PubMed     Abstract available

  211. ARENDS RM, Nelwan EJ, Soediro R, van Crevel R, et al
    Associations between impulsivity, risk behavior and HIV, HBV, HCV and syphilis seroprevalence among female prisoners in Indonesia: A cross-sectional study.
    PLoS One. 2019;14:e0207970.
    PubMed     Abstract available

  212. YANG RF, Liu Y, Zhao CY, Ding YX, et al
    A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?
    PLoS One. 2019;14:e0211795.
    PubMed     Abstract available

  213. HANSEN JF, Christiansen KM, Staugaard B, Moessner BK, et al
    Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C.
    PLoS One. 2019;14:e0212036.
    PubMed     Abstract available

  214. REUSCHEL E, Jilg W, Seelbach-Goebel B, Deml L, et al
    Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes.
    PLoS One. 2019;14:e0212800.
    PubMed     Abstract available

  215. SKOGLUND C, Lagging M, Castedal M
    No need to discontinue hepatitis C virus therapy at the time of liver transplantation.
    PLoS One. 2019;14:e0211437.
    PubMed     Abstract available

  216. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0212033.
    PubMed     Abstract available

  217. TAKEUCHI F, Ikeda S, Tsukamoto Y, Iwasawa Y, et al
    Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor.
    PLoS One. 2019;14:e0212233.
    PubMed     Abstract available

  218. VILLAR LM, Geloneze B, Vasques ACJ, Pires MLE, et al
    Prevalence of hepatitis B and hepatitis C among diabetes mellitus type 2 individuals.
    PLoS One. 2019;14:e0211193.
    PubMed     Abstract available

  219. JANG Y, Ahn SH, Lee K, Lee J, et al
    Psychometric evaluation of the Korean version of the Hepatitis B Quality of Life Questionnaire.
    PLoS One. 2019;14:e0213001.
    PubMed     Abstract available

  220. GRANADOS-GARCIA V, Flores YN, Diaz-Trejo LI, Mendez-Sanchez L, et al
    Estimating the prevalence of hepatitis C among intravenous drug users in upper middle income countries: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0212558.
    PubMed     Abstract available

  221. GANOVA-RAEVA L, Dimitrova Z, Alexiev I, Punkova L, et al
    HCV transmission in high-risk communities in Bulgaria.
    PLoS One. 2019;14:e0212350.
    PubMed     Abstract available

  222. JONES EA, Linas BP, Truong V, Burgess JF, et al
    Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    PLoS One. 2019;14:e0213745.
    PubMed     Abstract available

  223. CHIU SY, Chung HJ, Chen YT, Huang MS, et al
    A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1.
    PLoS One. 2019;14:e0208665.
    PubMed     Abstract available

  224. LE NGOC C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, et al
    Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam.
    PLoS One. 2019;14:e0212734.
    PubMed     Abstract available

  225. HUANG CH, Wu LS, Jeng WJ, Cheng YF, et al
    In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival.
    PLoS One. 2019;14:e0212770.
    PubMed     Abstract available

  226. WIBABARA Y, Banura C, Kalyango J, Karamagi C, et al
    Hepatitis B vaccination status and associated factors among undergraduate students of Makerere University College of Health Sciences.
    PLoS One. 2019;14:e0214732.
    PubMed     Abstract available

  227. BUGGISCH P, Wursthorn K, Stoehr A, Atanasov PK, et al
    Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    PLoS One. 2019;14:e0214795.
    PubMed     Abstract available

  228. AHSAN A, Khan AZ, Javed H, Mirza S, et al
    Estimation of hepatitis C prevalence in the Punjab province of Pakistan: A retrospective study on general population.
    PLoS One. 2019;14:e0214435.
    PubMed     Abstract available

  229. LEE YC, Hu TH, Hung CH, Lu SN, et al
    The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2019;14:e0214323.
    PubMed     Abstract available

  230. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Correction: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0215559.
    PubMed     Abstract available

  231. HANG PHAM TT, Le TX, Nguyen DT, Luu CM, et al
    Knowledge, attitudes and practices of hepatitis B prevention and immunization of pregnant women and mothers in northern Vietnam.
    PLoS One. 2019;14:e0208154.
    PubMed     Abstract available

  232. RAJAMOORTHY Y, Radam A, Taib NM, Rahim KA, et al
    Willingness to pay for hepatitis B vaccination in Selangor, Malaysia: A cross-sectional household survey.
    PLoS One. 2019;14:e0215125.
    PubMed     Abstract available

  233. ANABIRE NG, Aryee PA, Abdul-Karim A, Quaye O, et al
    Impact of malaria and hepatitis B co-infection on clinical and cytokine profiles among pregnant women.
    PLoS One. 2019;14:e0215550.
    PubMed     Abstract available

  234. BOATENG R, Mutocheluh M, Dompreh A, Obiri-Yeboah D, et al
    Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naive individuals in Kumasi, Ghana.
    PLoS One. 2019;14:e0215377.
    PubMed     Abstract available

  235. LATTHAPHASAVANG V, Vanhems P, Ngo-Giang-Huong N, Sibounlang P, et al
    Perinatal hepatitis B virus transmission in Lao PDR: A prospective cohort study.
    PLoS One. 2019;14:e0215011.
    PubMed     Abstract available

  236. MIAO N, Zheng H, Sun X, Shen L, et al
    Enhanced sentinel surveillance for hepatitis B infection in 200 counties in China, 2013-2016.
    PLoS One. 2019;14:e0215580.
    PubMed     Abstract available

  237. Retraction: Role of Hepatitis C Virus Induced Osteopontin in Epithelial to Mesenchymal Transition, Migration and Invasion of Hepatocytes.
    PLoS One. 2019;14:e0216026.

  238. Retraction: Activation of TGF-beta1 Promoter by Hepatitis C Virus-Induced AP-1 and Sp1: Role of TGF-beta1 in Hepatic Stellate Cell Activation and Invasion.
    PLoS One. 2019;14:e0216025.

  239. CHIKOVANI I, Ompad DC, Uchaneishvili M, Sulaberidze L, et al
    On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.
    PLoS One. 2019;14:e0216123.
    PubMed     Abstract available

  240. MPODY C, Thompson P, Tabala M, Ravelomanana NLR, et al
    Hepatitis B infection among pregnant and post-partum women living with HIV and on antiretroviral therapy in Kinshasa, DR Congo: A cross-sectional study.
    PLoS One. 2019;14:e0216293.
    PubMed     Abstract available

  241. YUAN Q, Wang F, Zheng H, Zhang G, et al
    Hepatitis B vaccination coverage among health care workers in China.
    PLoS One. 2019;14:e0216598.
    PubMed     Abstract available

  242. COSTA VD, Brandao-Mello CE, Nunes EP, Dos Santos Silva PGC, et al
    Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    PLoS One. 2019;14:e0216327.
    PubMed     Abstract available

  243. COSSAIS S, Schwarzinger M, Pol S, Fontaine H, et al
    Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage.
    PLoS One. 2019;14:e0215596.
    PubMed     Abstract available

  244. CHEN M, Ma Y, Chen H, Dai J, et al
    Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China.
    PLoS One. 2019;14:e0217010.
    PubMed     Abstract available

  245. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0215783.
    PubMed     Abstract available

  246. GEBOY AG, Nichols WL, Fernandez SJ, Desale S, et al
    Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system.
    PLoS One. 2019;14:e0216459.
    PubMed     Abstract available

  247. WILHELM B, Waddell L, Greig J, Young I, et al
    Systematic review and meta-analysis of the seroprevalence of hepatitis E virus in the general population across non-endemic countries.
    PLoS One. 2019;14:e0216826.
    PubMed     Abstract available

  248. CHAILLON A, Mehta SR, Hoenigl M, Solomon SS, et al
    Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
    PLoS One. 2019;14:e0217964.
    PubMed     Abstract available

  249. GASTALDI G, Gomes D, Schneiter P, Montet X, et al
    Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.
    PLoS One. 2019;14:e0217751.
    PubMed     Abstract available

  250. ROBERTS H, Boktor SW, Waller K, Daar ZS, et al
    Underreporting of Hepatitis B and C virus infections - Pennsylvania, 2001-2015.
    PLoS One. 2019;14:e0217455.
    PubMed     Abstract available

  251. MEDIC S, Anastassopoulou C, Milosevic V, Dragnic N, et al
    Declining seroprevalence of hepatitis A in Vojvodina, Serbia.
    PLoS One. 2019;14:e0217176.
    PubMed     Abstract available

  252. COFFIN PO, Santos GM, Behar E, Hern J, et al
    Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs.
    PLoS One. 2019;14:e0217471.
    PubMed     Abstract available

  253. RODRIGUEZ-OSORIO I, Mena A, Meijide H, Morano L, et al
    Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals.
    PLoS One. 2019;14:e0217052.
    PubMed     Abstract available

  254. PRABDIAL-SING N, Makhathini L, Smit SB, Manamela MJ, et al
    Hepatitis B sero-prevalence in children under 15 years of age in South Africa using residual samples from community-based febrile rash surveillance.
    PLoS One. 2019;14:e0217415.
    PubMed     Abstract available

  255. FURUTANI Y, Toguchi M, Shiozaki-Sato Y, Qin XY, et al
    An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.
    PLoS One. 2019;14:e0216139.
    PubMed     Abstract available

  256. PAVICIC IVELJA M, Ivic I, Dolic K, Mestrovic A, et al
    Evaluation of cerebrovascular reactivity in chronic hepatitis C patients using transcranial color Doppler.
    PLoS One. 2019;14:e0218206.
    PubMed     Abstract available

  257. BAROCAS JA, So-Armah K, Cheng DM, Lioznov D, et al
    Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naive persons with alcohol use in Russia.
    PLoS One. 2019;14:e0218852.
    PubMed     Abstract available

  258. IZQUIERDO L, Mellon G, Buchaillet C, Fac C, et al
    Prevalence of hepatitis E virus and reassessment of HIV and other hepatitis virus seroprevalences among French prison inmates.
    PLoS One. 2019;14:e0218482.
    PubMed     Abstract available

  259. HAERI MAZANDERANI A, Motaze NV, McCarthy K, Suchard M, et al
    Hepatitis A virus seroprevalence in South Africa - Estimates using routine laboratory data, 2005-2015.
    PLoS One. 2019;14:e0216033.
    PubMed     Abstract available

  260. BREZZI M, Bertisch B, Roelens M, Moradpour D, et al
    Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
    PLoS One. 2019;14:e0218706.
    PubMed     Abstract available

  261. OBIRI-YEBOAH D, Awuku YA, Adjei G, Cudjoe O, et al
    Post Hepatitis B vaccination sero-conversion among health care workers in the Cape Coast Metropolis of Ghana.
    PLoS One. 2019;14:e0219148.
    PubMed     Abstract available

  262. RAIHAN R, Akbar SMF, Al Mahtab M, Takahashi K, et al
    Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh.
    PLoS One. 2019;14:e0218744.
    PubMed     Abstract available

  263. CAMMAROTA S, Citarella A, Guida A, Conti V, et al
    The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study).
    PLoS One. 2019;14:e0219396.
    PubMed     Abstract available

  264. KATO K, Shimada N, Atsukawa M, Abe H, et al
    Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
    PLoS One. 2019;14:e0219022.
    PubMed     Abstract available

  265. CALNER P, Sperring H, Ruiz-Mercado G, Miller NS, et al
    HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center.
    PLoS One. 2019;14:e0218388.
    PubMed     Abstract available

  266. LAWANDI A, Cheng MP, Lee TC
    Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis.
    PLoS One. 2019;14:e0219347.
    PubMed     Abstract available

  267. FREMPONG MT, Ntiamoah P, Annani-Akollor ME, Owiredu WKBA, et al
    Hepatitis B and C infections in HIV-1 and non-HIV infected pregnant women in the Brong-Ahafo Region, Ghana.
    PLoS One. 2019;14:e0219922.
    PubMed     Abstract available

  268. BASKIC D, Vukovic V, Popovic S, Jovanovic D, et al
    Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.
    PLoS One. 2019;14:e0219508.
    PubMed     Abstract available

  269. JULICHER P, Chulanov VP, Pimenov NN, Chirkova E, et al
    Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis.
    PLoS One. 2019;14:e0219687.
    PubMed     Abstract available

  270. Retraction: Downgrading MELD Improves the Outcomes after Liver Transplantation in Patients with Acute-on-Chronic Hepatitis B Liver Failure.
    PLoS One. 2019;14:e0220487.

  271. WANG M, Wang Y, Liu Y, Wang H, et al
    SPSB2 inhibits hepatitis C virus replication by targeting NS5A for ubiquitination and degradation.
    PLoS One. 2019;14:e0219989.
    PubMed     Abstract available

  272. SPITZ N, Mello FCA, Moreira AS, Gusatti CS, et al
    Reconstruction of the spatial and temporal dynamics of hepatitis B virus genotype D in the Americas.
    PLoS One. 2019;14:e0220342.
    PubMed     Abstract available

  273. CHEN X, Chen Y, Liu C, Li X, et al
    Improved one-tube RT-PCR method for simultaneous detection and genotyping of duck hepatitis A virus subtypes 1 and 3.
    PLoS One. 2019;14:e0219750.
    PubMed     Abstract available

  274. PODLAHA O, Wu G, Downie B, Ramamurthy R, et al
    Genomic modeling of hepatitis B virus integration frequency in the human genome.
    PLoS One. 2019;14:e0220376.
    PubMed     Abstract available

  275. SOHOLM J, Holm DK, Mossner B, Madsen LW, et al
    Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
    PLoS One. 2019;14:e0220297.
    PubMed     Abstract available

  276. YEH ML, Huang CF, Huang CI, Dai CY, et al
    Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients.
    PLoS One. 2019;14:e0220663.
    PubMed     Abstract available

  277. BASKIC D, Vukovic V, Popovic S, Jovanovic D, et al
    Correction: Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.
    PLoS One. 2019;14:e0221142.
    PubMed     Abstract available

  278. PUGA MAM, Bandeira LM, Pompilio MA, Rezende GR, et al
    Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required.
    PLoS One. 2019;14:e0221265.
    PubMed     Abstract available

  279. KWO PY, Puenpatom A, Zhang Z, Hui SL, et al
    Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
    PLoS One. 2019;14:e0218759.
    PubMed     Abstract available

  280. Retraction: The Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection and Cirrhosis.
    PLoS One. 2019;14:e0222176.

  281. HUANG YJ, Yang SS, Yeh HZ, Chang CS, et al
    Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B.
    PLoS One. 2019;14:e0221958.
    PubMed     Abstract available

  282. PEREZ AB, Chueca N, Macias J, Pineda JA, et al
    Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
    PLoS One. 2019;14:e0221231.
    PubMed     Abstract available

  283. CHUGH Y, Dhiman RK, Premkumar M, Prinja S, et al
    Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    PLoS One. 2019;14:e0221769.
    PubMed     Abstract available

  284. UYEI J, Taddei TH, Kaplan DE, Chapko M, et al
    Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.
    PLoS One. 2019;14:e0221614.
    PubMed     Abstract available

  285. WETZEL D, Chan JA, Suckow M, Barbian A, et al
    Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha.
    PLoS One. 2019;14:e0221394.
    PubMed     Abstract available

  286. CROWLEY D, Cullen W, Lambert JS, Van Hout MC, et al
    Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care.
    PLoS One. 2019;14:e0222186.
    PubMed     Abstract available

  287. REZAEI N, Asadi-Lari M, Sheidaei A, Khademi S, et al
    Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis.
    PLoS One. 2019;14:e0198449.
    PubMed     Abstract available

  288. HELLE F, Brochot E, Fournier C, Descamps V, et al
    Correction: Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus.
    PLoS One. 2019;14:e0223022.
    PubMed     Abstract available

  289. EREN C
    An analysis on HBsAg, Anti-HCV, Anti-HIV(1/2) and VDRL test results in blood donors according to gender, age range and years.
    PLoS One. 2019;14:e0219709.
    PubMed     Abstract available

  290. SENKERIKOVA R, Frankova S, Jirsa M, Kreidlova M, et al
    PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
    PLoS One. 2019;14:e0222609.
    PubMed     Abstract available

  291. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0223287.
    PubMed     Abstract available

  292. LONDONO MC, Riveiro-Barciela M, Ahumada A, Munoz-Gomez R, et al
    Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    PLoS One. 2019;14:e0221567.
    PubMed     Abstract available

  293. O'CONNOR SM, Mixson-Hayden T, Ganova-Raeva L, Djibo DA, et al
    Integrated HIV surveillance finds recent adult hepatitis B virus (HBV) transmission and intermediate HBV prevalence among military in uncharacterized Caribbean country.
    PLoS One. 2019;14:e0222835.
    PubMed     Abstract available

  294. XI R, Kadur Lakshminarasimha Murthy P, Tung KL, Guy CD, et al
    SENP3-mediated host defense response contains HBV replication and restores protein synthesis.
    PLoS One. 2019;14:e0209179.
    PubMed     Abstract available

  295. SUMAYE R, Jansen F, Berkvens D, De Baets B, et al
    Rift Valley fever: An open-source transmission dynamics simulation model.
    PLoS One. 2019;14:e0209929.
    PubMed     Abstract available

  296. GARCIA A, Moore Boffi S, Gayet-Ageron A, Vernaz N, et al
    Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals.
    PLoS One. 2019;14:e0223649.
    PubMed     Abstract available

  297. RAYAN DA'AS S, Azzeh M
    Subgenotyping and genetic variability of hepatitis C virus in Palestine.
    PLoS One. 2019;14:e0222799.
    PubMed     Abstract available

  298. MA TL, Hu TH, Hung CH, Wang JH, et al
    Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
    PLoS One. 2019;14:e0222221.
    PubMed     Abstract available

  299. HANG PHAM TT, Le TX, Nguyen DT, Luu CM, et al
    Knowledge, attitudes and medical practice regarding hepatitis B prevention and management among healthcare workers in Northern Vietnam.
    PLoS One. 2019;14:e0223733.
    PubMed     Abstract available

  300. FANTILLI AC, Trinks J, Marciano S, Zarate F, et al
    Unexpected high seroprevalence of hepatitis E virus in patients with alcohol-related cirrhosis.
    PLoS One. 2019;14:e0224404.
    PubMed     Abstract available

  301. KUO YH, Kee KM, Hsu NT, Wang JH, et al
    Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening.
    PLoS One. 2019;14:e0222196.
    PubMed     Abstract available

  302. GARDINI I, Bartoli M, Conforti M, Mennini FS, et al
    Estimation of the number of HCV-positive patients in Italy.
    PLoS One. 2019;14:e0223668.
    PubMed     Abstract available

  303. MOHD SUAN MA, Said SM, Lim PY, Azman AZF, et al
    Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study.
    PLoS One. 2019;14:e0224459.
    PubMed     Abstract available

  304. BLACKARD JT, Kong L, Rouster SD, Karns R, et al
    CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
    PLoS One. 2019;14:e0224523.
    PubMed     Abstract available

  305. ZHENG Z, Lin J, Lu Z, Su J, et al
    Mortality risk in the population of HIV-positive individuals in Southern China: A cohort study.
    PLoS One. 2019;14:e0210856.
    PubMed     Abstract available

  306. MANUEL SOUSA J, Vergara M, Pulido F, Sanchez Antolin G, et al
    Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r +/- dasabuvir +/- ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    PLoS One. 2019;14:e0225061.
    PubMed     Abstract available

  307. PRPIC J, Keros T, Vucelja M, Bjedov L, et al
    First evidence of hepatitis E virus infection in a small mammal (yellow-necked mouse) from Croatia.
    PLoS One. 2019;14:e0225583.
    PubMed     Abstract available

  308. ZUCKERMAN AD, Douglas A, Whelchel K, Choi L, et al
    Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
    PLoS One. 2019;14:e0225434.
    PubMed     Abstract available

  309. HAMADEH A, Feng Z, Krahn M, Wong WWL, et al
    A model-based framework for chronic hepatitis C prevalence estimation.
    PLoS One. 2019;14:e0225366.
    PubMed     Abstract available

  310. CHEN MB, Wang H, Zheng QH, Zheng XW, et al
    Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0224773.
    PubMed     Abstract available

  311. SHENGE JA, Odaibo GN, Olaleye DO
    Correction: Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0225679.
    PubMed     Abstract available

  312. MUCKE MM, Maasoumy B, Dietz J, Mucke VT, et al
    Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy.
    PLoS One. 2019;14:e0224751.
    PubMed     Abstract available

  313. SUZUKI Y, Maekawa S, Komatsu N, Sato M, et al
    HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers.
    PLoS One. 2019;14:e0212559.
    PubMed     Abstract available

  314. Retraction: Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    PLoS One. 2019;14:e0225971.

  315. HO CH, Chang TT, Chien RN
    Telbivudine on IgG-associated hypergammaglobulinemia and TGF-beta1 hyperactivity in hepatitis B virus-related liver cirrhosis.
    PLoS One. 2019;14:e0225482.
    PubMed     Abstract available

  316. PARK DW, Lee YJ, Chang W, Park JH, et al
    Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease.
    PLoS One. 2019;14:e0212771.
    PubMed     Abstract available

  317. BLUMEL B, Diercke M, Sagebiel D, Gilsdorf A, et al
    Positive predictive value of the German notification system for infectious diseases: Surveillance data from eight local health departments, Berlin, 2012.
    PLoS One. 2019;14:e0212908.
    PubMed     Abstract available

  318. ADJEI CA, Stutterheim SE, Naab F, Ruiter RAC, et al
    Barriers to chronic Hepatitis B treatment and care in Ghana: A qualitative study with people with Hepatitis B and healthcare providers.
    PLoS One. 2019;14:e0225830.
    PubMed     Abstract available

  319. Retraction: Circulating FoxP3+ regulatory T and interleukin17-producing Th17 cells actively influence HBV clearance in de novo Hepatitis B virus infected patients after orthotopic liver transplantation.
    PLoS One. 2019;14:e0226148.

  320. PAGE K, Evans JL, Hahn JA, Vickerman P, et al
    HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco.
    PLoS One. 2019;14:e0226166.
    PubMed     Abstract available

  321. WOLDEGIORGIS AE, Erku W, Medhin G, Berhe N, et al
    Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia.
    PLoS One. 2019;14:e0226890.
    PubMed     Abstract available

  322. AYANA DA, Mulu A, Mihret A, Seyoum B, et al
    Hepatitis B virus seromarkers among HIV infected adults on ART: An unmet need for HBV screening in eastern Ethiopia.
    PLoS One. 2019;14:e0226922.
    PubMed     Abstract available

  323. FILHO HRM, Bierrenbach ALS, Capuani MLD, Mendrone A Jr, et al
    Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study.
    PLoS One. 2019;14:e0226566.
    PubMed     Abstract available

  324. SHIFERAW E, Tadilo W, Melkie I, Shiferaw M, et al
    Sero-prevalence and trends of transfusion-transmissible infections among blood donors at Bahir Dar district blood bank, northwest Ethiopia: A four year retrospective study.
    PLoS One. 2019;14:e0214755.
    PubMed     Abstract available

  325. SEKAMATTE M, Riad MH, Tekleghiorghis T, Linthicum KJ, et al
    Individual-based network model for Rift Valley fever in Kabale District, Uganda.
    PLoS One. 2019;14:e0202721.
    PubMed     Abstract available

  326. ABGHOUR S, Zro K, Mouahid M, Tahiri F, et al
    Isolation and characterization of fowl aviadenovirus serotype 11 from chickens with inclusion body hepatitis in Morocco.
    PLoS One. 2019;14:e0227004.
    PubMed     Abstract available

  327. GANTNER P, Cotte L, Allavena C, Bani-Sadr F, et al
    Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
    PLoS One. 2019;14:e0215464.
    PubMed     Abstract available

  328. MORRIS MD, Andrew E, Tan JY, Maher L, et al
    Injecting-related trust, cooperation, intimacy, and power as key factors influencing risk perception among drug injecting partnerships.
    PLoS One. 2019;14:e0217811.
    PubMed     Abstract available

  329. CHENG YW, Chang YC, Chen YL, Chen RC, et al
    Feasibility of measuring spleen stiffness with MR elastography and splenic volume to predict hepatic fibrosis stage.
    PLoS One. 2019;14:e0217876.
    PubMed     Abstract available

  330. HAVRANEK KE, White LA, Lanchy JM, Lodmell JS, et al
    Transcriptome profiling in Rift Valley fever virus infected cells reveals modified transcriptional and alternative splicing programs.
    PLoS One. 2019;14:e0217497.
    PubMed     Abstract available

  331. QI X, Gui X, Zhuang K
    Establishment and characterization of HBV-associated B lymphocytes with an immortalization potential.
    PLoS One. 2019;14:e0217161.
    PubMed     Abstract available

  332. THEE S, Kruger R, von Bernuth H, Meisel C, et al
    Screening and treatment for tuberculosis in a cohort of unaccompanied minor refugees in Berlin, Germany.
    PLoS One. 2019;14:e0216234.
    PubMed     Abstract available

  333. HETTEGGER P, Huber J, Passecker K, Soldo R, et al
    High similarity of IgG antibody profiles in blood and saliva opens opportunities for saliva based serology.
    PLoS One. 2019;14:e0218456.
    PubMed     Abstract available

  334. MEJIDO DCP, de Oliveira JM, Gaspar AMC, Gardinali NR, et al
    Evidences of HEV genotype 3 persistence and reactivity in liver parenchyma from experimentally infected cynomolgus monkeys (Macaca fascicularis).
    PLoS One. 2019;14:e0218472.
    PubMed     Abstract available

  335. BITEYE B, Fall AG, Seck MT, Ciss M, et al
    Host-feeding patterns of Aedes (Aedimorphus) vexans arabiensis, a Rift Valley Fever virus vector in the Ferlo pastoral ecosystem of Senegal.
    PLoS One. 2019;14:e0215194.
    PubMed     Abstract available

  336. YEN YH, Chen CH, Hung CH, Wang JH, et al
    Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data.
    PLoS One. 2019;14:e0222605.
    PubMed     Abstract available

  337. GALLAY P, Ure D, Bobardt M, Chatterji U, et al
    The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
    PLoS One. 2019;14:e0217433.
    PubMed     Abstract available

  338. MOHAMED SOHAIMI N, Bejo MH, Omar AR, Ideris A, et al
    Molecular characterization of fowl adenovirus isolate of Malaysia attenuated in chicken embryo liver cells and its pathogenicity and immunogenicity in chickens.
    PLoS One. 2019;14:e0225863.
    PubMed     Abstract available

  339. SIMONS RRL, Croft S, Rees E, Tearne O, et al
    Using species distribution models to predict potential hot-spots for Rift Valley Fever establishment in the United Kingdom.
    PLoS One. 2019;14:e0225250.
    PubMed     Abstract available

    January 2018
  340. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2018;13:e0190803.
    PubMed     Abstract available

  341. CHARRE C, Cotte L, Kramer R, Miailhes P, et al
    Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men.
    PLoS One. 2018;13:e0190340.
    PubMed     Abstract available

  342. CHEN SH, Lai HC, Chiang IP, Su WP, et al
    Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0190455.
    PubMed     Abstract available

  343. LEE CS, Jung YJ, Kim SS, Cheong JY, et al
    Liver volume-based prediction model stratifies risks for hepatocellular carcinoma in chronic hepatitis B patients on surveillance.
    PLoS One. 2018;13:e0190261.
    PubMed     Abstract available

  344. CARIMO AA, Gudo ES, Maueia C, Mabunda N, et al
    First report of occult hepatitis B infection among ART naive HIV seropositive individuals in Maputo, Mozambique.
    PLoS One. 2018;13:e0190775.
    PubMed     Abstract available

  345. BIVIGOU-MBOUMBA B, Amougou-Atsama M, Zoa-Assoumou S, M'boyis Kamdem H, et al
    Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
    PLoS One. 2018;13:e0190592.
    PubMed     Abstract available

  346. FARSHADPOUR F, Taherkhani R, Ravanbod MR, Eghbali SS, et al
    Prevalence, risk factors and molecular evaluation of hepatitis E virus infection among pregnant women resident in the northern shores of Persian Gulf, Iran.
    PLoS One. 2018;13:e0191090.
    PubMed     Abstract available

  347. LEE HJ, Kim SJ, Kweon YO, Park SY, et al
    Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
    PLoS One. 2018;13:e0190581.
    PubMed     Abstract available

  348. MAROT A, Dubois M, Trepo E, Moreno C, et al
    Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis.
    PLoS One. 2018;13:e0190823.
    PubMed     Abstract available

  349. OBIRI-YEBOAH D, Asante Awuku Y, Adu J, Pappoe F, et al
    Sero-prevalence and risk factors for hepatitis E virus infection among pregnant women in the Cape Coast Metropolis, Ghana.
    PLoS One. 2018;13:e0191685.
    PubMed     Abstract available

  350. HEIL J, Hoebe CJPA, Loo IHMV, Cals JWL, et al
    Hepatitis E prevalence in a sexual high-risk population compared to the general population.
    PLoS One. 2018;13:e0191798.
    PubMed     Abstract available

  351. BOLOTIN S, Feld JJ, Garber G, Wong WWL, et al
    Population-based estimate of hepatitis C virus prevalence in Ontario, Canada.
    PLoS One. 2018;13:e0191184.
    PubMed     Abstract available

  352. CHENG CH, Lin CC, Chen HL, Lin IT, et al
    Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.
    PLoS One. 2018;13:e0191799.
    PubMed     Abstract available

  353. DEL CAMPO JA, Garcia-Valdecasas M, Gil-Gomez A, Rojas A, et al
    Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
    PLoS One. 2018;13:e0191805.
    PubMed     Abstract available

  354. NDJOYI-MBIGUINO A, Kombe Kombe AJ, Bivigou-Mboumba B, Zoa-Assoumou S, et al
    Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon.
    PLoS One. 2018;13:e0190529.
    PubMed     Abstract available

  355. SAFREED-HARMON K, Hetherington KL, Aleman S, Alho H, et al
    Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
    PLoS One. 2018;13:e0190146.
    PubMed     Abstract available

  356. ZAHR NM
    Peripheral TNFalpha elevations in abstinent alcoholics are associated with hepatitis C infection.
    PLoS One. 2018;13:e0191586.
    PubMed     Abstract available

  357. DE PINA-ARAUJO IIM, Spitz N, Soares CC, Niel C, et al
    Hepatitis B virus genotypes A1, A2 and E in Cape Verde: Unequal distribution through the islands and association with human flows.
    PLoS One. 2018;13:e0192595.
    PubMed     Abstract available

  358. HUGHES E, Hopkins LJ, Parker R
    Survival from alcoholic hepatitis has not improved over time.
    PLoS One. 2018;13:e0192393.
    PubMed     Abstract available

  359. KELLY ML, Riordan SM, Bopage R, Lloyd AR, et al
    Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.
    PLoS One. 2018;13:e0192763.
    PubMed     Abstract available

  360. ANADOL E, Lust K, Boesecke C, Schwarze-Zander C, et al
    Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.
    PLoS One. 2018;13:e0191118.
    PubMed     Abstract available

  361. RATTANAVIPAPONG W, Anothaisintawee T, Teerawattananon Y
    Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
    PLoS One. 2018;13:e0193112.
    PubMed     Abstract available

  362. TARAMASSO L, Di Biagio A, Bovis F, Nicolini LA, et al
    Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin in HIV/HCV co-infected patients.
    PLoS One. 2018;13:e0192627.
    PubMed     Abstract available

  363. AMBACHEW H, Zheng M, Pappoe F, Shen J, et al
    Genotyping and sero-virological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia.
    PLoS One. 2018;13:e0193177.
    PubMed     Abstract available

  364. CHENG PN, Chiu YC, Chiu HC, Chien SC, et al
    The characteristics of residents with unawareness of hepatitis C virus infection in community.
    PLoS One. 2018;13:e0193251.
    PubMed     Abstract available

  365. MAPOURE NY, Budzi MN, Eloumou SAFB, Malongue A, et al
    Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study.
    PLoS One. 2018;13:e0192406.
    PubMed     Abstract available

  366. BALSITIS S, Gali V, Mason PJ, Chaniewski S, et al
    Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.
    PLoS One. 2018;13:e0190058.
    PubMed     Abstract available

  367. MAUNOURY F, Clement A, Nwankwo C, Levy-Bachelot L, et al
    Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    PLoS One. 2018;13:e0194329.
    PubMed     Abstract available

  368. AN J, Kim JW, Shim JH, Han S, et al
    Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study.
    PLoS One. 2018;13:e0193232.
    PubMed     Abstract available

  369. DI POTO C, He S, Varghese RS, Zhao Y, et al
    Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection.
    PLoS One. 2018;13:e0192748.
    PubMed     Abstract available

  370. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0194163.
    PubMed     Abstract available

  371. ZEKRI AN, El-Sisi ER, Youssef ASE, Kamel MM, et al
    MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.
    PLoS One. 2018;13:e0193709.
    PubMed     Abstract available

  372. CARABALLO CORTES K, Rosinska M, Janiak M, Stepien M, et al
    Next-generation sequencing analysis of a cluster of hepatitis C virus infections in a haematology and oncology center.
    PLoS One. 2018;13:e0194816.
    PubMed     Abstract available

  373. SAUVAGE V, Boizeau L, Candotti D, Vandenbogaert M, et al
    Early MinION nanopore single-molecule sequencing technology enables the characterization of hepatitis B virus genetic complexity in clinical samples.
    PLoS One. 2018;13:e0194366.
    PubMed     Abstract available

  374. NEMOZ B, Roger L, Leroy V, Poveda JD, et al
    Evaluation of the cobas(R) GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.
    PLoS One. 2018;13:e0194396.
    PubMed     Abstract available

  375. NGUYEN HH, Shaheen AA, Baeza N, Lytvyak E, et al
    Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS).
    PLoS One. 2018;13:e0193960.
    PubMed     Abstract available

  376. LI CW, Yang CJ, Sun HY, Tsai MS, et al
    Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan.
    PLoS One. 2018;13:e0194149.
    PubMed     Abstract available

  377. BRAND RF, Rostal MK, Kemp A, Anyamba A, et al
    A phytosociological analysis and description of wetland vegetation and ecological factors associated with locations of high mortality for the 2010-11 Rift Valley fever outbreak in South Africa.
    PLoS One. 2018;13:e0191585.
    PubMed     Abstract available

  378. DES JARLAIS DC, Cooper HLF, Arasteh K, Feelemyer J, et al
    Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.
    PLoS One. 2018;13:e0194799.
    PubMed     Abstract available

  379. Retraction: rs10499194 polymorphism in the tumor necrosis factor-alpha inducible protein 3 (TNFAIP3) gene is associated with type-1 autoimmune hepatitis risk in Chinese Han population.
    PLoS One. 2018;13:e0195181.

  380. TI L, Socias ME, Wood E, Milloy MJ, et al
    The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.
    PLoS One. 2018;13:e0194162.
    PubMed     Abstract available

  381. KHAN T, Zaman G, Saleh Alshomrani A
    Spreading dynamic of acute and carrier hepatitis B with nonlinear incidence.
    PLoS One. 2018;13:e0191914.
    PubMed     Abstract available

  382. YAMAZAKI T, Joshita S, Umemura T, Usami Y, et al
    Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0195632.
    PubMed     Abstract available

  383. GOLIZEH M, Melendez-Pena CE, Ward BJ, Saeed S, et al
    Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.
    PLoS One. 2018;13:e0195148.
    PubMed     Abstract available

  384. BELYHUN Y, Liebert UG, Maier M
    Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
    PLoS One. 2018;13:e0191970.
    PubMed     Abstract available

  385. DE LA FUENTE C, Pinkham C, Dabbagh D, Beitzel B, et al
    Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection.
    PLoS One. 2018;13:e0191983.
    PubMed     Abstract available

  386. EKO MBA JM, Bisseye C, Ntsame Ndong JM, Mombo LE, et al
    Prevalent hepatitis B surface antigen among first-time blood donors in Gabon.
    PLoS One. 2018;13:e0194285.
    PubMed     Abstract available

  387. HAN B, Yuan Q, Shi Y, Wei L, et al
    The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China.
    PLoS One. 2018;13:e0195455.
    PubMed     Abstract available

  388. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0195575.
    PubMed     Abstract available

  389. FRIEDMAN A, Siewe N
    Chronic hepatitis B virus and liver fibrosis: A mathematical model.
    PLoS One. 2018;13:e0195037.
    PubMed     Abstract available

  390. HUGHES E, Hopkins LJ, Parker R
    Correction: Survival from alcoholic hepatitis has not improved over time.
    PLoS One. 2018;13:e0195857.
    PubMed     Abstract available

  391. LU Y, Jin X, Duan CA, Chang F, et al
    Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China.
    PLoS One. 2018;13:e0195117.
    PubMed     Abstract available

  392. HAMADA K, Saitoh S, Nishino N, Fukushima D, et al
    Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response.
    PLoS One. 2018;13:e0195173.
    PubMed     Abstract available

  393. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    PLoS One. 2018;13:e0194704.
    PubMed     Abstract available

  394. FISHER KA, Cahill LM, Broyles S, Rorke M, et al
    Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use.
    PLoS One. 2018;13:e0196157.
    PubMed     Abstract available

  395. CHIU YM, Lai MS, Chan KA
    Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
    PLoS One. 2018;13:e0196210.
    PubMed     Abstract available

  396. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    PLoS One. 2018;13:e0196301.
    PubMed     Abstract available

  397. OKUBO H, Ando H, Sorin Y, Nakadera E, et al
    Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
    PLoS One. 2018;13:e0196747.
    PubMed     Abstract available

  398. PARK H, Jeong D, Nguyen P, Henry L, et al
    Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.
    PLoS One. 2018;13:e0196452.
    PubMed     Abstract available

  399. JIMENEZ-SOUSA MA, Gomez-Moreno AZ, Pineda-Tenor D, Medrano LM, et al
    The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
    PLoS One. 2018;13:e0197115.
    PubMed     Abstract available

  400. DEMSISS W, Seid A, Fiseha T
    Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia.
    PLoS One. 2018;13:e0196539.
    PubMed     Abstract available

  401. FENG Y, Feng YM, Wang S, Xu F, et al
    High seroprevalence of hepatitis E virus in the ethnic minority populations in Yunnan, China.
    PLoS One. 2018;13:e0197577.
    PubMed     Abstract available

  402. TSUKAMOTO Y, Ikeda S, Uwai K, Taguchi R, et al
    Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction.
    PLoS One. 2018;13:e0197664.
    PubMed     Abstract available

  403. MAWATARI S, Oda K, Tabu K, Ijuin S, et al
    The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
    PLoS One. 2018;13:e0198642.
    PubMed     Abstract available

  404. YAMAMIYA D, Mizukoshi E, Kaji K, Terashima T, et al
    Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides.
    PLoS One. 2018;13:e0198264.
    PubMed     Abstract available

  405. NAKANO T, Moriya K, Koike K, Horie T, et al
    Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells.
    PLoS One. 2018;13:e0198345.
    PubMed     Abstract available

  406. BLANCO RY, Loureiro CL, Villalba JA, Sulbaran YF, et al
    Decreasing prevalence of Hepatitis B and absence of Hepatitis C Virus infection in the Warao indigenous population of Venezuela.
    PLoS One. 2018;13:e0197662.
    PubMed     Abstract available

  407. BRUNI R, Villano U, Equestre M, Chionne P, et al
    Hepatitis E virus genotypes and subgenotypes causing acute hepatitis, Bulgaria, 2013-2015.
    PLoS One. 2018;13:e0198045.
    PubMed     Abstract available

  408. GROTTENTHALER JM, Werner CR, Steurer M, Spengler U, et al
    Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PLoS One. 2018;13:e0197544.
    PubMed     Abstract available

  409. MULLER SF, Konig A, Doring B, Glebe D, et al
    Characterisation of the hepatitis B virus cross-species transmission pattern via Na+/taurocholate co-transporting polypeptides from 11 New World and Old World primate species.
    PLoS One. 2018;13:e0199200.
    PubMed     Abstract available

  410. ZUCKERMAN A, Douglas A, Nwosu S, Choi L, et al
    Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.
    PLoS One. 2018;13:e0199174.
    PubMed     Abstract available

  411. HAINSWORTH SW, Dietze PM, Wilson DP, Sutton B, et al
    Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas.
    PLoS One. 2018;13:e0198336.
    PubMed     Abstract available

  412. YEN YH, Kuo FY, Kee KM, Chang KC, et al
    APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
    PLoS One. 2018;13:e0199760.
    PubMed     Abstract available

  413. BUTI M, Manzano ML, Morillas RM, Garcia-Retortillo M, et al
    Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
    PLoS One. 2018;13:e0199926.
    PubMed     Abstract available

  414. YAYA I, Roux P, Marcellin F, Wittkop L, et al
    Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
    PLoS One. 2018;13:e0199874.
    PubMed     Abstract available

  415. KIM TH, Lee EJ, Choi JH, Yim SY, et al
    Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B.
    PLoS One. 2018;13:e0199094.
    PubMed     Abstract available

  416. CHEN YY, Fang WH, Wang CC, Kao TW, et al
    Increased body fat percentage in patients with hepatitis B and C virus infection.
    PLoS One. 2018;13:e0200164.
    PubMed     Abstract available

  417. SCHAEFER B, Viveiros A, Al-Zoairy R, Blach S, et al
    Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    PLoS One. 2018;13:e0200750.
    PubMed     Abstract available

  418. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Correction: Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0200866.
    PubMed     Abstract available

  419. ZHERNAKOVA DV, Kliver S, Cherkasov N, Tamazian G, et al
    Analytical "bake-off" of whole genome sequencing quality for the Genome Russia project using a small cohort for autoimmune hepatitis.
    PLoS One. 2018;13:e0200423.
    PubMed     Abstract available

  420. MIOTTO N, Mendes LC, Zanaga LP, Lazarini MSK, et al
    All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
    PLoS One. 2018;13:e0199941.
    PubMed     Abstract available

  421. MALAGNINO V, Salpini R, Maffongelli G, Battisti A, et al
    High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance.
    PLoS One. 2018;13:e0195045.
    PubMed     Abstract available

  422. TIEU HV, Laeyendecker O, Nandi V, Rose R, et al
    Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City.
    PLoS One. 2018;13:e0200269.
    PubMed     Abstract available

  423. WEI L, Wedemeyer H, Liaw YF, Chan HL, et al
    No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
    PLoS One. 2018;13:e0199198.
    PubMed     Abstract available

  424. XAYDALASOUK K, Strobel M, Buisson Y, Black AP, et al
    Seroprevalence and risk factors of hepatitis B and C virus infections in female workers of Lao garment factories.
    PLoS One. 2018;13:e0199919.
    PubMed     Abstract available

  425. XIONG QF, Xiong T, Huang P, Zhong YD, et al
    Early predictors of acute hepatitis B progression to liver failure.
    PLoS One. 2018;13:e0201049.
    PubMed     Abstract available

  426. SOOD A, Suryaprasad A, Trickey A, Kanchi S, et al
    The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey.
    PLoS One. 2018;13:e0200461.
    PubMed     Abstract available

  427. CUYPERS L, Perez AB, Chueca N, Aldamiz-Echevarria T, et al
    Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.
    PLoS One. 2018;13:e0201268.
    PubMed     Abstract available

  428. EVANS H, Balasegaram S, Douthwaite S, Hunter L, et al
    An innovative approach to increase viral hepatitis diagnoses and linkage to care using opt-out testing and an integrated care pathway in a London Emergency Department.
    PLoS One. 2018;13:e0198520.
    PubMed     Abstract available

  429. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Correction: Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0201423.
    PubMed     Abstract available

  430. TAT TRUNG N, Duong DC, Tong HV, Hien TTT, et al
    Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma.
    PLoS One. 2018;13:e0196081.
    PubMed     Abstract available

  431. EVON DM, Stewart PW, Amador J, Serper M, et al
    A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    PLoS One. 2018;13:e0196908.
    PubMed     Abstract available

  432. NEESGAARD B, Ruhwald M, Krarup HB, Weis N, et al
    Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.
    PLoS One. 2018;13:e0201629.
    PubMed     Abstract available

  433. JUN BG, Kim YD, Kim SG, Kim YS, et al
    Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study.
    PLoS One. 2018;13:e0201316.
    PubMed     Abstract available

  434. ELIZALDE MM, Perez PS, Sevic I, Grasso D, et al
    HBV subgenotypes F1b and F4 replication induces an incomplete autophagic process in hepatocytes: Role of BCP and preCore mutations.
    PLoS One. 2018;13:e0197109.
    PubMed     Abstract available

  435. MASSAQUOI TA, Burke RM, Yang G, Lakoh S, et al
    Cross sectional study of chronic hepatitis B prevalence among healthcare workers in an urban setting, Sierra Leone.
    PLoS One. 2018;13:e0201820.
    PubMed     Abstract available

  436. DU Z, Dong J, Bi J, Bai R, et al
    Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy.
    PLoS One. 2018;13:e0195336.
    PubMed     Abstract available

  437. POSUWAN N, Vorayingyong A, Jaroonvanichkul V, Wasitthankasem R, et al
    Implementation of hepatitis B vaccine in high-risk young adults with waning immunity.
    PLoS One. 2018;13:e0202637.
    PubMed     Abstract available

  438. GOUNTAS I, Sypsa V, Blach S, Razavi H, et al
    HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.
    PLoS One. 2018;13:e0202109.
    PubMed     Abstract available

  439. HSIEH YC, Jeng WJ, Huang CH, Teng W, et al
    Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    PLoS One. 2018;13:e0202777.
    PubMed     Abstract available

  440. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy.
    PLoS One. 2018;13:e0202991.
    PubMed     Abstract available

  441. WHITMILL A, Kim S, Rojas V, Gulraiz F, et al
    Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection.
    PLoS One. 2018;13:e0202524.
    PubMed     Abstract available

  442. AL MAHTAB M, Akbar SMF, Aguilar JC, Guillen G, et al
    Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
    PLoS One. 2018;13:e0201236.
    PubMed     Abstract available

  443. GOYAL A, Romero-Severson EO
    Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
    PLoS One. 2018;13:e0203831.
    PubMed     Abstract available

  444. SILVA CMD, Peder LD, Guelere AM, Horvath JD, et al
    Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
    PLoS One. 2018;13:e0203272.
    PubMed     Abstract available

  445. XING YF, Zhou DQ, He JS, Wei CS, et al
    Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China.
    PLoS One. 2018;13:e0203220.
    PubMed     Abstract available

  446. WANG YW, Shen ZZ, Jiang Y
    Comparison of ARIMA and GM(1,1) models for prediction of hepatitis B in China.
    PLoS One. 2018;13:e0201987.
    PubMed     Abstract available

  447. OWUSU M, Bonney JK, Annan AA, Mawuli G, et al
    Aetiology of viral hepatitis among jaundiced patients presenting to a tertiary hospital in Ghana.
    PLoS One. 2018;13:e0203699.
    PubMed     Abstract available

  448. LUK KC, Coller KE, Dawson GJ, Cloherty GA, et al
    Identification of a putative novel genotype 3/rabbit hepatitis E virus (HEV) recombinant.
    PLoS One. 2018;13:e0203618.
    PubMed     Abstract available

  449. DAS S, Opoku J, Allston A, Kharfen M, et al
    Detecting spatial clusters of HIV and hepatitis coinfections.
    PLoS One. 2018;13:e0203674.
    PubMed     Abstract available

  450. KENNEDY K, Graham SM, Arora N, Shuhart MC, et al
    Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis.
    PLoS One. 2018;13:e0204031.
    PubMed     Abstract available

  451. ZHANG XS, Iacono GL
    Estimating human-to-human transmissibility of hepatitis A virus in an outbreak at an elementary school in China, 2011.
    PLoS One. 2018;13:e0204201.
    PubMed     Abstract available

  452. VALENCIA LA ROSA J, Ryan P, Alvaro-Meca A, Troya J, et al
    HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination.
    PLoS One. 2018;13:e0204795.
    PubMed     Abstract available

  453. BOTTINO FO, Gardinali NR, Salvador SBS, Figueiredo AS, et al
    Cynomolgus monkeys (Macaca fascicularis) experimentally and naturally infected with hepatitis E virus: The bone marrow as a possible new viral target.
    PLoS One. 2018;13:e0205039.
    PubMed     Abstract available

  454. UCHIDA Y, Naiki K, Kouyama JI, Sugawara K, et al
    Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    PLoS One. 2018;13:e0205600.
    PubMed     Abstract available

  455. SOSA-JURADO F, Melendez-Mena D, Rosas-Murrieta NH, Guzman-Flores B, et al
    Effectiveness of PCR primers for the detection of occult hepatitis B virus infection in Mexican patients.
    PLoS One. 2018;13:e0205356.
    PubMed     Abstract available

  456. DA SILVA EN, Baker A, Alshekaili J, Karpe K, et al
    A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease.
    PLoS One. 2018;13:e0204477.
    PubMed     Abstract available

  457. JUANBELTZ R, Martinez-Baz I, San Miguel R, Goni-Esarte S, et al
    Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.
    PLoS One. 2018;13:e0205277.
    PubMed     Abstract available

  458. SCHNELL G, Krishnan P, Tripathi R, Beyer J, et al
    Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    PLoS One. 2018;13:e0205186.
    PubMed     Abstract available

  459. FAHMY AM, Khabir M, Blanchet M, Labonte P, et al
    LC3B is not recruited along with the autophagy elongation complex (ATG5-12/16L1) at HCV replication site and is dispensable for viral replication.
    PLoS One. 2018;13:e0205189.
    PubMed     Abstract available

  460. TAKAHASHI A, Moriya K, Ohira H, Arinaga-Hino T, et al
    Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.
    PLoS One. 2018;13:e0204772.
    PubMed     Abstract available

  461. MCCLURE MW, Berliba E, Tsertsvadze T, Streinu-Cercel A, et al
    Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
    PLoS One. 2018;13:e0204974.
    PubMed     Abstract available

  462. NISBET AI, Omuse G, Revathi G, Adam RD, et al
    Seroprevalence data at a private teaching hospital in Kenya: An examination of Toxoplasma gondii, cytomegalovirus, rubella, hepatitis A, and Entamoeba histolytica.
    PLoS One. 2018;13:e0204867.
    PubMed     Abstract available

  463. MARTINEZ-RODRIGUEZ ML, Uribe-Noguez LA, Arroyo-Anduiza CI, Mata-Marin JA, et al
    Prevalence and risk factors of Occult Hepatitis C infections in blood donors from Mexico City.
    PLoS One. 2018;13:e0205659.
    PubMed     Abstract available

  464. SUIJKERBUIJK AWM, van Hoek AJ, Koopsen J, de Man RA, et al
    Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.
    PLoS One. 2018;13:e0207037.
    PubMed     Abstract available

  465. CHENG PN, Chiu HC, Chiu YC, Chen SC, et al
    Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community.
    PLoS One. 2018;13:e0206947.
    PubMed     Abstract available

  466. LIU C, Wang L, Xie H, Zhang L, et al
    The relationship between serum hepatitis B virus DNA level and liver histology in patients with chronic HBV infection.
    PLoS One. 2018;13:e0206060.
    PubMed     Abstract available

  467. JANG TY, Yeh ML, Huang CI, Lin ZY, et al
    Association of hyperuricemia with disease severity in chronic hepatitis C patients.
    PLoS One. 2018;13:e0207043.
    PubMed     Abstract available

  468. INOUE T, Ito Y, Nishizawa N, Eshima K, et al
    RAMP1 in Kupffer cells is a critical regulator in immune-mediated hepatitis.
    PLoS One. 2018;13:e0200432.
    PubMed     Abstract available

  469. KHAN B, Duncan I, Saad M, Schaefer D, et al
    Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment.
    PLoS One. 2018;13:e0206356.
    PubMed     Abstract available

  470. BUTI M, Dominguez-Hernandez R, Casado MA, Sabater E, et al
    Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
    PLoS One. 2018;13:e0208036.
    PubMed     Abstract available

  471. CHOWDHURY P, Sahuc ME, Rouille Y, Riviere C, et al
    Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
    PLoS One. 2018;13:e0198226.
    PubMed     Abstract available

  472. RAJAMOORTHY Y, Radam A, Taib NM, Rahim KA, et al
    The relationship between perceptions and self-paid hepatitis B vaccination: A structural equation modeling approach.
    PLoS One. 2018;13:e0208402.
    PubMed     Abstract available

  473. RAU M, Schmitt J, Berg T, Kremer AE, et al
    Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.
    PLoS One. 2018;13:e0208225.
    PubMed     Abstract available

  474. ABADIE R, Goldenberg S, Welch-Lazoritz M, Fisher CB, et al
    Establishing trust in HIV/HCV research among people who inject drugs (PWID): Insights from empirical research.
    PLoS One. 2018;13:e0208410.
    PubMed     Abstract available

  475. BOUACIDA L, Suin V, Hutse V, Boudewijns M, et al
    Distribution of HCV genotypes in Belgium from 2008 to 2015.
    PLoS One. 2018;13:e0207584.
    PubMed     Abstract available

  476. JUANBELTZ R, Perez-Garcia A, Aguinaga A, Martinez-Baz I, et al
    Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.
    PLoS One. 2018;13:e0208554.
    PubMed     Abstract available

  477. MADDEN A, Hopwood M, Neale J, Treloar C, et al
    Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    PLoS One. 2018;13:e0207226.
    PubMed     Abstract available

  478. LAWRENCE YA, Dangott LJ, Rodrigues-Hoffmann A, Steiner JM, et al
    Proteomic analysis of liver tissue from dogs with chronic hepatitis.
    PLoS One. 2018;13:e0208394.
    PubMed     Abstract available

  479. BADAWI A, Di Giuseppe G, Arora P
    Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017).
    PLoS One. 2018;13:e0208839.
    PubMed     Abstract available

  480. DIMEGLIO C, Beau F, Broult J, Gouy P, et al
    Hepatitis E prevalence in French Polynesian blood donors.
    PLoS One. 2018;13:e0208934.
    PubMed     Abstract available

  481. GUALERZI A, Bellan M, Smirne C, Tran Minh M, et al
    Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents.
    PLoS One. 2018;13:e0209216.
    PubMed     Abstract available

  482. PARK H, Jeong D, Nguyen P, Henry L, et al
    Correction: Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.
    PLoS One. 2018;13:e0209715.
    PubMed     Abstract available

  483. GALLACH M, Vergara M, da Costa JP, Miquel M, et al
    Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2018;13:e0208112.
    PubMed     Abstract available

  484. BILLA O, Chalouni M, Salmon D, Poizot-Martin I, et al
    Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.
    PLoS One. 2018;13:e0208657.
    PubMed     Abstract available

  485. ALBERTS CJ, Schim van der Loeff MF, Sadik S, Zuure FR, et al
    Hepatitis E virus seroprevalence and determinants in various study populations in the Netherlands.
    PLoS One. 2018;13:e0208522.
    PubMed     Abstract available

  486. PAPIC N, Zidovec Lepej S, Gorenec L, Grgic I, et al
    The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C.
    PLoS One. 2018;13:e0209481.
    PubMed     Abstract available

  487. KAWAGISHI N, Suda G, Nakamura A, Kimura M, et al
    Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    PLoS One. 2018;13:e0209615.
    PubMed     Abstract available

  488. LIU CH, Liu CJ, Su TH, Yang HC, et al
    Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
    PLoS One. 2018;13:e0209299.
    PubMed     Abstract available

  489. ABE K, Takahashi A, Fujita M, Imaizumi H, et al
    Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease.
    PLoS One. 2018;13:e0198757.
    PubMed     Abstract available

  490. MATSUMOTO K, Wu Y, Kitazawa T, Fujita S, et al
    Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections.
    PLoS One. 2018;13:e0199188.
    PubMed     Abstract available

  491. MULLHAUPT B, Bruggmann P, Bihl F, Blach S, et al
    Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    PLoS One. 2018;13:e0209374.
    PubMed     Abstract available

  492. KAKIZAKI M, Yamamoto Y, Yabuta S, Kurosaki N, et al
    The immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes.
    PLoS One. 2018;13:e0205886.
    PubMed     Abstract available

  493. SPENGLER JR, McElroy AK, Harmon JR, Coleman-McCray JD, et al
    Human immune cell engraftment does not alter development of severe acute Rift Valley fever in mice.
    PLoS One. 2018;13:e0201104.
    PubMed     Abstract available

  494. MERIKI HD, Tufon KA, Anong DN, Tony NJ, et al
    Vaccine uptake and immune responses to HBV infection amongst vaccinated and non-vaccinated healthcare workers, household and sexual contacts to chronically infected HBV individuals in the South West Region of Cameroon.
    PLoS One. 2018;13:e0200157.
    PubMed     Abstract available

  495. MANGIA A, Losappio R, Cenderello G, Potenza D, et al
    Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    PLoS One. 2018;13:e0200568.
    PubMed     Abstract available

  496. ABEL S, Cuzin L, Da Cunha S, Bolivard JM, et al
    Reaching the WHO target of testing persons in jails in prisons will need diverse efforts and resources.
    PLoS One. 2018;13:e0202985.
    PubMed     Abstract available

  497. TUFON KA, Anong DN, Meriki HD, Georges TD, et al
    Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon.
    PLoS One. 2018;13:e0203312.
    PubMed     Abstract available

  498. VALERIAN DM, Mauka WI, Kajeguka DC, Mgabo M, et al
    Prevalence and causes of blood donor deferrals among clients presenting for blood donation in northern Tanzania.
    PLoS One. 2018;13:e0206487.
    PubMed     Abstract available

  499. DAVIS SM, Davidov D, Kristjansson AL, Zullig K, et al
    Qualitative case study of needle exchange programs in the Central Appalachian region of the United States.
    PLoS One. 2018;13:e0205466.
    PubMed     Abstract available

  500. BARANYI A, Meinitzer A, Rothenhausler HB, Amouzadeh-Ghadikolai O, et al
    Metabolomics approach in the investigation of depression biomarkers in pharmacologically induced immune-related depression.
    PLoS One. 2018;13:e0208238.
    PubMed     Abstract available

  501. WERNER RN, Gaskins M, Nast A, Dressler C, et al
    Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis.
    PLoS One. 2018;13:e0208107.
    PubMed     Abstract available

  502. CORREA ASM, Lamarao LM, Vieira PCM, de Castro RBH, et al
    Prevalence, incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil.
    PLoS One. 2018;13:e0208414.
    PubMed     Abstract available

    January 2017
  503. COUTO I, Victoria M, Veloso VG, Rodrigues L, et al
    Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection.
    PLoS One. 2017;12:e0174453.
    PubMed     Abstract available

  504. GARDINALI NR, Guimaraes JR, Melgaco JG, Kevorkian YB, et al
    Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy.
    PLoS One. 2017;12:e0174070.
    PubMed     Abstract available

  505. YOSHIOKA T, Tatsumi T, Miyagi T, Mukai K, et al
    Frequency and role of NKp46 and NKG2A in hepatitis B virus infection.
    PLoS One. 2017;12:e0174103.
    PubMed     Abstract available

  506. RALLON N, Garcia M, Garcia-Samaniego J, Rodriguez N, et al
    HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells.
    PLoS One. 2017;12:e0173943.
    PubMed     Abstract available

  507. GUPTA N, Kabahizi J, Mukabatsinda C, Walker TD, et al
    "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
    PLoS One. 2017;12:e0174148.
    PubMed     Abstract available

  508. GUINOISEAU T, Moreau A, Hohnadel G, Ngo-Giang-Huong N, et al
    Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification.
    PLoS One. 2017;12:e0174852.
    PubMed     Abstract available

  509. HUANG YJ, Chang CS, Peng YC, Yeh HZ, et al
    On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
    PLoS One. 2017;12:e0174046.
    PubMed     Abstract available

  510. LOWE PP, Gyongyosi B, Satishchandran A, Iracheta-Vellve A, et al
    Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice.
    PLoS One. 2017;12:e0174544.
    PubMed     Abstract available

  511. CHEN HC, Chung CH, Wang CH, Lin JC, et al
    Increased risk of sudden sensorineural hearing loss in patients with hepatitis virus infection.
    PLoS One. 2017;12:e0175266.
    PubMed     Abstract available

  512. YE Q, Yin W, Zhang L, Xiao H, et al
    The value of grip test, lysophosphatidlycholines, glycerophosphocholine, ornithine, glucuronic acid decrement in assessment of nutritional and metabolic characteristics in hepatitis B cirrhosis.
    PLoS One. 2017;12:e0175165.
    PubMed     Abstract available

  513. KACZMAREK DJ, Kokordelis P, Kramer B, Glassner A, et al
    Alterations of the NK cell pool in HIV/HCV co-infection.
    PLoS One. 2017;12:e0174465.
    PubMed     Abstract available

  514. CHEN H, Chen L
    Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.
    PLoS One. 2017;12:e0175189.
    PubMed     Abstract available

  515. KOMOLMIT P, Charoensuk K, Thanapirom K, Suksawatamnuay S, et al
    Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.
    PLoS One. 2017;12:e0174608.
    PubMed     Abstract available

  516. FERNANDEZ-CABALLERO JA, Alvarez M, Chueca N, Perez AB, et al
    The cobas(R) HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice.
    PLoS One. 2017;12:e0175564.
    PubMed     Abstract available

  517. YANG CM, Yoon JC, Park JH, Lee JM, et al
    Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
    PLoS One. 2017;12:e0175793.
    PubMed     Abstract available

  518. CHLIBEK R, Smetana J, Sosovickova R, Gal P, et al
    Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.
    PLoS One. 2017;12:e0175525.
    PubMed     Abstract available

  519. NGUYEN HM, Sy BT, Trung NT, Hoan NX, et al
    Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam.
    PLoS One. 2017;12:e0175304.
    PubMed     Abstract available

  520. DU H, Yang J, Bai J, Ming K, et al
    A flavone-polysaccharide based prescription attenuates the mitochondrial dysfunction induced by duck hepatitis A virus type 1.
    PLoS One. 2017;12:e0175495.
    PubMed     Abstract available

  521. LE GUILLOU-GUILLEMETTE H, Pivert A, Bouthry E, Henquell C, et al
    Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.
    PLoS One. 2017;12:e0174651.
    PubMed     Abstract available

  522. FAN Z, EnQiang C, Yao DL, LiBo Y, et al
    Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure treated with an artificial liver support system.
    PLoS One. 2017;12:e0175332.
    PubMed     Abstract available

  523. NEFFATTI H, Lebraud P, Hottelet C, Gharbi J, et al
    Southern Tunisia: A still high endemicity area for hepatitis A.
    PLoS One. 2017;12:e0175887.
    PubMed     Abstract available

  524. XU E, Cao H, Lin L, Liu H, et al
    rs10499194 polymorphism in the tumor necrosis factor-alpha inducible protein 3 (TNFAIP3) gene is associated with type-1 autoimmune hepatitis risk in Chinese Han population.
    PLoS One. 2017;12:e0176471.
    PubMed     Abstract available

  525. CAPILENO YA, Van den Bergh R, Donchunk D, Hinderaker SG, et al
    Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0175562.
    PubMed     Abstract available

  526. SLOT E, Zaaijer HL, Molier M, Van den Hurk K, et al
    Meat consumption is a major risk factor for hepatitis E virus infection.
    PLoS One. 2017;12:e0176414.
    PubMed     Abstract available

  527. PENE V, Lemasson M, Harper F, Pierron G, et al
    Role of cleavage at the core-E1 junction of hepatitis C virus polyprotein in viral morphogenesis.
    PLoS One. 2017;12:e0175810.
    PubMed     Abstract available

  528. JEONG H, Baek SY, Kim SW, Eun YH, et al
    Comorbidities of rheumatoid arthritis: Results from the Korean National Health and Nutrition Examination Survey.
    PLoS One. 2017;12:e0176260.
    PubMed     Abstract available

  529. FRIAS M, Rivero-Juarez A, Tellez F, Perez-Perez M, et al
    Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.
    PLoS One. 2017;12:e0177141.
    PubMed     Abstract available

  530. GENCAY M, Hubner K, Gohl P, Seffner A, et al
    Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population.
    PLoS One. 2017;12:e0172101.
    PubMed     Abstract available

  531. MOQUEET N, Kanagaratham C, Gill MJ, Hull M, et al
    A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.
    PLoS One. 2017;12:e0176282.
    PubMed     Abstract available

  532. DIRKSEN K, Spee B, Penning LC, van den Ingh TSGAM, et al
    Gene expression patterns in the progression of canine copper-associated chronic hepatitis.
    PLoS One. 2017;12:e0176826.
    PubMed     Abstract available

  533. SUN J, Robinson L, Lee NL, Welles S, et al
    No contribution of lifestyle and environmental exposures to gender discrepancy of liver disease severity in chronic hepatitis b infection: Observations from the Haimen City cohort.
    PLoS One. 2017;12:e0175482.
    PubMed     Abstract available

  534. BIRGER RB, Le T, Kouyos RD, Grenfell BT, et al
    The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.
    PLoS One. 2017;12:e0177195.
    PubMed     Abstract available

  535. PANDOLFI R, Ramos de Almeida D, Alves Pinto M, Kreutz LC, et al
    In house ELISA based on recombinant ORF2 protein underline high prevalence of IgG anti-hepatitis E virus amongst blood donors in south Brazil.
    PLoS One. 2017;12:e0176409.
    PubMed     Abstract available

  536. CHANG CC, Hsu HJ, Yen JH, Lo SY, et al
    A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.
    PLoS One. 2017;12:e0177383.
    PubMed     Abstract available

  537. NAKAMURA M, Kanda T, Jiang X, Haga Y, et al
    Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
    PLoS One. 2017;12:e0177302.
    PubMed     Abstract available

  538. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.
    PLoS One. 2017;12:e0177022.
    PubMed     Abstract available

  539. BAEZ PA, Lopez MC, Duque-Jaramillo A, Pelaez D, et al
    First evidence of the Hepatitis E virus in environmental waters in Colombia.
    PLoS One. 2017;12:e0177525.
    PubMed     Abstract available

  540. D'ARMINIO MONFORTE A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, et al
    Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    PLoS One. 2017;12:e0177402.
    PubMed     Abstract available

  541. AGGARWAL R, Chen Q, Goel A, Seguy N, et al
    Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
    PLoS One. 2017;12:e0176503.
    PubMed     Abstract available

  542. CENTO V, Nguyen THT, Di Carlo D, Biliotti E, et al
    Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    PLoS One. 2017;12:e0177352.
    PubMed     Abstract available

  543. ECKHARDT B, Winkelstein ER, Shu MA, Carden MR, et al
    Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.
    PLoS One. 2017;12:e0177341.
    PubMed     Abstract available

  544. JANG Y, Kim JH, Lee K
    Validation of the revised piper fatigue scale in Koreans with chronic hepatitis B.
    PLoS One. 2017;12:e0177690.
    PubMed     Abstract available

  545. HAN Z, Yin Y, Zhang Y, Ehrhardt S, et al
    Knowledge of and attitudes towards hepatitis B and its transmission from mother to child among pregnant women in Guangdong Province, China.
    PLoS One. 2017;12:e0178671.
    PubMed     Abstract available

  546. HUNDIE GB, Raj VS, GebreMichael D, Pas SD, et al
    Genetic diversity of hepatitis C virus in Ethiopia.
    PLoS One. 2017;12:e0179064.
    PubMed     Abstract available

  547. LOWE PP, Gyongyosi B, Satishchandran A, Iracheta-Vellve A, et al
    Correction: Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice.
    PLoS One. 2017;12:e0179070.
    PubMed     Abstract available

  548. ZHENG H, Zou AE, Saad MA, Wang XQ, et al
    Alcohol-dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma.
    PLoS One. 2017;12:e0178547.
    PubMed     Abstract available

  549. NAIK AS, Owsianka A, Palmer BA, O'Halloran CJ, et al
    Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.
    PLoS One. 2017;12:e0175349.
    PubMed     Abstract available

  550. EL HADAD S, Al-Hamdan H, Linjawi S
    Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia.
    PLoS One. 2017;12:e0178225.
    PubMed     Abstract available

  551. JANG TY, Lin PC, Huang CI, Liao YM, et al
    Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.
    PLoS One. 2017;12:e0178883.
    PubMed     Abstract available

  552. TAUBERT R, Hardtke-Wolenski M, Noyan F, Lalanne C, et al
    Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis.
    PLoS One. 2017;12:e0179074.
    PubMed     Abstract available

  553. CHIU NC, Su CW, Liu CA, Huang YH, et al
    Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections.
    PLoS One. 2017;12:e0178841.
    PubMed     Abstract available

  554. SAHA D, Pal A, Sarkar N, Das D, et al
    Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India.
    PLoS One. 2017;12:e0179035.
    PubMed     Abstract available

  555. HARRIS BJ, Holzmayer V, Qureshi H, Khan MA, et al
    Hepatitis B genotypes and surface antigen mutants present in Pakistani blood donors.
    PLoS One. 2017;12:e0178988.
    PubMed     Abstract available

  556. ALVARO-MECA A, Berenguer J, Diaz A, Micheloud D, et al
    Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.
    PLoS One. 2017;12:e0179493.
    PubMed     Abstract available

  557. CHU PS, Nakamoto N, Taniki N, Ojiro K, et al
    On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
    PLoS One. 2017;12:e0179096.
    PubMed     Abstract available

  558. NDOW G, Gore ML, Shimakawa Y, Suso P, et al
    Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes.
    PLoS One. 2017;12:e0179025.
    PubMed     Abstract available

  559. LEE JW, Kim W, Kwon EK, Kim Y, et al
    Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
    PLoS One. 2017;12:e0179094.
    PubMed     Abstract available

  560. CHENG ST, Tang H, Ren JH, Chen X, et al
    Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo.
    PLoS One. 2017;12:e0179605.
    PubMed     Abstract available

  561. OU X, Mao S, Cao J, Cheng A, et al
    Comparative analysis of virus-host interactions caused by a virulent and an attenuated duck hepatitis A virus genotype 1.
    PLoS One. 2017;12:e0178993.
    PubMed     Abstract available

  562. WU YT, Li X, Liu ZL, Xu Z, et al
    Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0179680.
    PubMed     Abstract available

  563. CAPILENO YA, Van den Bergh R, Donchuk D, Hinderaker SG, et al
    Correction: Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0180286.
    PubMed     Abstract available

  564. MASCIA C, Vita S, Zuccala P, Marocco R, et al
    Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
    PLoS One. 2017;12:e0179400.
    PubMed     Abstract available

  565. ELSHERIF O, Bannan C, Keating S, McKiernan S, et al
    Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.
    PLoS One. 2017;12:e0178398.
    PubMed     Abstract available

  566. GUILLOT C, Martel N, Berby F, Bordes I, et al
    Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.
    PLoS One. 2017;12:e0179697.
    PubMed     Abstract available

  567. LIN HC, Xirasagar S, Lee HC, Huang CC, et al
    Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder.
    PLoS One. 2017;12:e0179312.
    PubMed     Abstract available

  568. LIU Z, Li S, Liu Y, Guo W, et al
    PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection.
    PLoS One. 2017;12:e0180390.
    PubMed     Abstract available

  569. ISHIZAKI A, Tran VT, Nguyen CH, Tanimoto T, et al
    Discrepancies in prevalence trends for HIV, hepatitis B virus, and hepatitis C virus in Haiphong, Vietnam from 2007 to 2012.
    PLoS One. 2017;12:e0179616.
    PubMed     Abstract available

  570. LIU T, Wang F, Zhang S, Wang F, et al
    Whole-gene analysis of two groups of hepatitis B virus C/D inter-genotype recombinant strains isolated in Tibet, China.
    PLoS One. 2017;12:e0179846.
    PubMed     Abstract available

  571. BELAUNZARAN-ZAMUDIO PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, et al
    Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico.
    PLoS One. 2017;12:e0179931.
    PubMed     Abstract available

  572. ABEBE M, Ali I, Ayele S, Overbo J, et al
    Seroprevalence and risk factors of Hepatitis E Virus infection among pregnant women in Addis Ababa, Ethiopia.
    PLoS One. 2017;12:e0180078.
    PubMed     Abstract available

  573. SHIU TY, Huang SM, Shih YL, Chu HC, et al
    Correction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2017;12:e0181299.
    PubMed     Abstract available

  574. SNOW KJ, Richards AH, Kinner SA
    Use of multiple data sources to estimate hepatitis C seroprevalence among prisoners: A retrospective cohort study.
    PLoS One. 2017;12:e0180646.
    PubMed     Abstract available

  575. RENDON JC, Cortes-Mancera F, Restrepo-Gutierrez JC, Hoyos S, et al
    Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia.
    PLoS One. 2017;12:e0180447.
    PubMed     Abstract available

  576. LEVENTER-ROBERTS M, Hammerman A, Brufman I, Hoshen M, et al
    Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
    PLoS One. 2017;12:e0176858.
    PubMed     Abstract available

  577. JANG YR, Shin Y, Jin CE, Koo B, et al
    Molecular detection of Coxiella burnetii from the formalin-fixed tissues of Q fever patients with acute hepatitis.
    PLoS One. 2017;12:e0180237.
    PubMed     Abstract available

  578. LOPEZ-RODRIGUEZ R, Hernandez-Bartolome A, Borque MJ, Rodriguez-Munoz Y, et al
    Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C.
    PLoS One. 2017;12:e0180927.
    PubMed     Abstract available

  579. DALGARD O, Weiland O, Noraberg G, Karlsen L, et al
    Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    PLoS One. 2017;12:e0179764.
    PubMed     Abstract available

  580. DIESTELHORST J, Junge N, Schlue J, Falk CS, et al
    Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy.
    PLoS One. 2017;12:e0181107.
    PubMed     Abstract available

  581. ANDRE-GARNIER E, Besse B, Rodallec A, Ribeyrol O, et al
    An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.
    PLoS One. 2017;12:e0179562.
    PubMed     Abstract available

  582. NEUKAM K, Martinez AP, Culasso ACA, Ridruejo E, et al
    NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b.
    PLoS One. 2017;12:e0182193.
    PubMed     Abstract available

  583. MATSUO J, Do SH, Yamamoto C, Nagashima S, et al
    Clustering infection of hepatitis B virus genotype B4 among residents in Vietnam, and its genomic characters both intra- and extra-family.
    PLoS One. 2017;12:e0177248.
    PubMed     Abstract available

  584. RUSSELLI G, Pizzillo P, Iannolo G, Barbera F, et al
    HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation.
    PLoS One. 2017;12:e0181683.
    PubMed     Abstract available

  585. SABET S, George MA, El-Shorbagy HM, Bassiony H, et al
    Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene.
    PLoS One. 2017;12:e0181723.
    PubMed     Abstract available

  586. MERDAN M, Bekiryazici Z, Kesemen T, Khaniyev T, et al
    Deterministic stability and random behavior of a Hepatitis C model.
    PLoS One. 2017;12:e0181571.
    PubMed     Abstract available

  587. STELZL E, Haas B, Bauer B, Zhang S, et al
    First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing.
    PLoS One. 2017;12:e0181273.
    PubMed     Abstract available

  588. CHOTUN N, Preiser W, van Rensburg CJ, Fernandez P, et al
    Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience.
    PLoS One. 2017;12:e0181267.
    PubMed     Abstract available

  589. TAN WG, Zubkova I, Kachko A, Wells F, et al
    Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
    PLoS One. 2017;12:e0181578.
    PubMed     Abstract available

  590. HUGHES MG JR, Tucker WW, Reddy S, Brier ME, et al
    Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition.
    PLoS One. 2017;12:e0180719.
    PubMed     Abstract available

  591. KIM BH, Choi HY, Ki M, Kim KA, et al
    Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea.
    PLoS One. 2017;12:e0182391.
    PubMed     Abstract available

  592. GOUVEIA LR, Santos JC, Silva RD, Batista AD, et al
    Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics.
    PLoS One. 2017;12:e0182196.
    PubMed     Abstract available

  593. SAGNELLI C, Uberti-Foppa C, Hasson H, Bellini G, et al
    Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
    PLoS One. 2017;12:e0181890.
    PubMed     Abstract available

  594. NAGAOKI Y, Imamura M, Aikata H, Daijo K, et al
    The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    PLoS One. 2017;12:e0182710.
    PubMed     Abstract available

  595. KIM YA, Trinh S, Thura S, Kyi KP, et al
    Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.
    PLoS One. 2017;12:e0181603.
    PubMed     Abstract available

  596. HUANG CM, Chang KC, Hung CH, Chiu KW, et al
    Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.
    PLoS One. 2017;12:e0182204.
    PubMed     Abstract available

  597. WISSKIRCHEN K, Metzger K, Schreiber S, Asen T, et al
    Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.
    PLoS One. 2017;12:e0182936.
    PubMed     Abstract available

  598. GOSSELIN A, Lelievre E, Ravalihasy A, Lydie N, et al
    "Times Are Changing": The Impact of HIV Diagnosis on Sub-Saharan Migrants' Lives in France.
    PLoS One. 2017;12:e0170226.
    PubMed     Abstract available

  599. WU CK, Liang CM, Hsu CN, Hung TH, et al
    The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation.
    PLoS One. 2017;12:e0169884.
    PubMed     Abstract available

  600. NIU C, Livingston CM, Li L, Beran RK, et al
    The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection.
    PLoS One. 2017;12:e0169648.
    PubMed     Abstract available

  601. LIU X, He L, Han J, Wang L, et al
    Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer.
    PLoS One. 2017;12:e0170605.
    PubMed     Abstract available

  602. CHO YE, Im EJ, Moon PG, Mezey E, et al
    Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury.
    PLoS One. 2017;12:e0172463.
    PubMed     Abstract available

  603. DE WEGGHELEIRE A, An S, De Baetselier I, Soeung P, et al
    A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening.
    PLoS One. 2017;12:e0183530.
    PubMed     Abstract available

  604. BUTT ZA, Shrestha N, Wong S, Kuo M, et al
    A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia.
    PLoS One. 2017;12:e0183609.
    PubMed     Abstract available

  605. GUO G, Zhang L, Ye S, Hu Y, et al
    Polymorphisms and features of cytomegalovirus UL144 and UL146 in congenitally infected neonates with hepatic involvement.
    PLoS One. 2017;12:e0171959.
    PubMed     Abstract available

  606. CARRIERI MP, Marcellin F, Fressard L, Preau M, et al
    Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey).
    PLoS One. 2017;12:e0171645.
    PubMed     Abstract available

  607. MANICKAM C, Wachtman L, Martinot AJ, Giavedoni LD, et al
    Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).
    PLoS One. 2017;12:e0170240.
    PubMed     Abstract available

  608. MORSICA G, Bagaglio S, Spagnuolo V, Castagna A, et al
    Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.
    PLoS One. 2017;12:e0184128.
    PubMed     Abstract available

  609. SHIER MK, Iles JC, El-Wetidy MS, Ali HH, et al
    Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia.
    PLoS One. 2017;12:e0184163.
    PubMed     Abstract available

  610. HERMETET C, Dubois F, Gaudy-Graffin C, Bacq Y, et al
    Continuum of hepatitis C care in France: A 20-year cohort study.
    PLoS One. 2017;12:e0183232.
    PubMed     Abstract available

  611. KJAERGAARD M, Thiele M, Jansen C, Staehr Madsen B, et al
    High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal.
    PLoS One. 2017;12:e0173992.
    PubMed     Abstract available

  612. GARBA RM, Gadanya MA
    The role of intervention mapping in designing disease prevention interventions: A systematic review of the literature.
    PLoS One. 2017;12:e0174438.
    PubMed     Abstract available

  613. ZHENG Z, Sze CW, Keng CT, Al-Haddawi M, et al
    Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model.
    PLoS One. 2017;12:e0184127.
    PubMed     Abstract available

  614. DAVIES J, Li SQ, Tong SY, Baird RW, et al
    Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population.
    PLoS One. 2017;12:e0184082.
    PubMed     Abstract available

  615. GOMEZ-MORENO AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sanchez-Ruano JJ, et al
    Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.
    PLoS One. 2017;12:e0184404.
    PubMed     Abstract available

  616. VUTIEN P, Jin M, Le MH, Nguyen P, et al
    Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.
    PLoS One. 2017;12:e0183851.
    PubMed     Abstract available

  617. WANG L, Cao M, Wei QL, Zhao ZH, et al
    A new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice.
    PLoS One. 2017;12:e0175992.
    PubMed     Abstract available

  618. GONZALEZ R, De la Rosa AJ, Rufini A, Rodriguez-Hernandez MA, et al
    Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation.
    PLoS One. 2017;12:e0174326.
    PubMed     Abstract available

  619. KEATING SM, Dodge JL, Norris PJ, Heitman J, et al
    The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    PLoS One. 2017;12:e0181004.
    PubMed     Abstract available

  620. BUTI M, Manzano ML, Morillas RM, Garcia-Retortillo M, et al
    Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
    PLoS One. 2017;12:e0184550.
    PubMed     Abstract available

  621. TUDESQ JJ, Dunyach-Remy C, Combescure C, Doncesco R, et al
    Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients.
    PLoS One. 2017;12:e0183372.
    PubMed     Abstract available

  622. ROSINSKA M, Parda N, Kolakowska A, Godzik P, et al
    Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.
    PLoS One. 2017;12:e0185055.
    PubMed     Abstract available

  623. UITTE DE WILLIGE S, Keane FM, Bowen DG, Malfliet JJMC, et al
    Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
    PLoS One. 2017;12:e0178987.
    PubMed     Abstract available

  624. KRAUSKOPF J, de Kok TM, Schomaker SJ, Gosink M, et al
    Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human.
    PLoS One. 2017;12:e0177928.
    PubMed     Abstract available

  625. WANG H, Zhang W, Gu H, Chen W, et al
    Identification and characterization of two linear epitope motifs in hepatitis E virus ORF2 protein.
    PLoS One. 2017;12:e0184947.
    PubMed     Abstract available

  626. HOU J, Brouwer WP, Kreefft K, Gama L, et al
    Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection.
    PLoS One. 2017;12:e0179920.
    PubMed     Abstract available

  627. GONZALES-GUSTAVSON E, Timoneda N, Fernandez-Cassi X, Caballero A, et al
    Identification of sapovirus GV.2, astrovirus VA3 and novel anelloviruses in serum from patients with acute hepatitis of unknown aetiology.
    PLoS One. 2017;12:e0185911.
    PubMed     Abstract available

  628. NAGATY A, Abd El-Wahab EW
    Real-life results of sofosbuvir based therapy in chronic hepatitis C -naive and -experienced patients in Egypt.
    PLoS One. 2017;12:e0184654.
    PubMed     Abstract available

  629. NOSAKA T, Naito T, Hiramatsu K, Ohtani M, et al
    Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B.
    PLoS One. 2017;12:e0185442.
    PubMed     Abstract available

  630. YANG CK, Wang XK, Liao XW, Han CY, et al
    Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma.
    PLoS One. 2017;12:e0182208.
    PubMed     Abstract available

  631. BIADGO B, Shiferaw E, Woldu B, Alene KA, et al
    Transfusion-transmissible viral infections among blood donors at the North Gondar district blood bank, northwest Ethiopia: A three year retrospective study.
    PLoS One. 2017;12:e0180416.
    PubMed     Abstract available

  632. PARASCHIV S, Banica L, Nicolae I, Niculescu I, et al
    Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users.
    PLoS One. 2017;12:e0185866.
    PubMed     Abstract available

  633. JARAMILLO CM, de La Hoz F, Porras A, di Filippo D, et al
    Characterization of hepatitis B virus in Amerindian children and mothers from Amazonas State, Colombia.
    PLoS One. 2017;12:e0181643.
    PubMed     Abstract available

  634. CHAMBAL LM, Samo Gudo E, Carimo A, Corte Real R, et al
    HBV infection in untreated HIV-infected adults in Maputo, Mozambique.
    PLoS One. 2017;12:e0181836.
    PubMed     Abstract available

  635. VAN LOO IHM, Dukers-Muijrers NHTM, Heuts R, van der Sande MAB, et al
    Screening for HIV, hepatitis B and syphilis on dried blood spots: A promising method to better reach hidden high-risk populations with self-collected sampling.
    PLoS One. 2017;12:e0186722.
    PubMed     Abstract available

  636. UEMURA H, Tsukada K, Mizushima D, Aoki T, et al
    Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    PLoS One. 2017;12:e0186255.
    PubMed     Abstract available

  637. BURCHILL MA, Roby JA, Crochet N, Wind-Rotolo M, et al
    Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
    PLoS One. 2017;12:e0186213.
    PubMed     Abstract available

  638. LEE YL, Lin KY, Cheng CY, Li CW, et al
    Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan.
    PLoS One. 2017;12:e0186338.
    PubMed     Abstract available

  639. LY HJ, Lokugamage N, Nishiyama S, Ikegami T, et al
    Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.
    PLoS One. 2017;12:e0185194.
    PubMed     Abstract available

  640. LI T, Gao Y, Dong Q, Wang H, et al
    Degree sums and dense spanning trees.
    PLoS One. 2017;12:e0184912.
    PubMed     Abstract available

  641. DUFFY D, Mottez E, Ainsworth S, Buivan TP, et al
    An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms.
    PLoS One. 2017;12:e0183084.
    PubMed     Abstract available

  642. LUBYOVA B, Hodek J, Zabransky A, Prouzova H, et al
    PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core.
    PLoS One. 2017;12:e0186982.
    PubMed     Abstract available

  643. CHEN YI MEI SLG, Thompson AJ, Christensen B, Cunningham G, et al
    Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    PLoS One. 2017;12:e0185609.
    PubMed     Abstract available

  644. YOON JG, Choi MJ, Yoon JW, Noh JY, et al
    Seroprevalence and disease burden of acute hepatitis A in adult population in South Korea.
    PLoS One. 2017;12:e0186257.
    PubMed     Abstract available

  645. PALIWAL D, Joshi P, Panda SK
    Hepatitis E Virus (HEV) egress: Role of BST2 (Tetherin) and interferon induced long non- coding RNA (lncRNA) BISPR.
    PLoS One. 2017;12:e0187334.
    PubMed     Abstract available

  646. OKA S, Furukawa H, Yasunami M, Kawasaki A, et al
    HLA-DRB1 and DQB1 alleles in Japanese type 1 autoimmune hepatitis: The predisposing role of the DR4/DR8 heterozygous genotype.
    PLoS One. 2017;12:e0187325.
    PubMed     Abstract available

  647. DULTZ G, Graubard BI, Martin P, Welker MW, et al
    Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry.
    PLoS One. 2017;12:e0186898.
    PubMed     Abstract available

  648. HARFOUCHE M, Chemaitelly H, Kouyoumjian SP, Mahmud S, et al
    Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.
    PLoS One. 2017;12:e0187177.
    PubMed     Abstract available

  649. ROZERA G, Fabbri G, Lorenzini P, Mastrorosa I, et al
    Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    PLoS One. 2017;12:e0187095.
    PubMed     Abstract available

  650. MAROT A, Henrion J, Knebel JF, Moreno C, et al
    Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    PLoS One. 2017;12:e0186715.
    PubMed     Abstract available

  651. KONDILI LA, Gaeta GB, Brunetto MR, Di Leo A, et al
    Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
    PLoS One. 2017;12:e0185728.
    PubMed     Abstract available

  652. LOGGI E, Galli S, Vitale G, Di Donato R, et al
    Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
    PLoS One. 2017;12:e0187755.
    PubMed     Abstract available

  653. LANINI S, Minosse C, Vairo F, Garbuglia A, et al
    A large ongoing outbreak of hepatitis A predominantly affecting young males in Lazio, Italy; August 2016 - March 2017.
    PLoS One. 2017;12:e0185428.
    PubMed     Abstract available

  654. YOSHIOKA N, Deguchi M, Hagiya H, Kagita M, et al
    Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations.
    PLoS One. 2017;12:e0187661.
    PubMed     Abstract available

  655. YANG Z, Jia M, Liu G, Hao H, et al
    Genomic sequencing identifies a few mutations driving the independent origin of primary liver tumors in a chronic hepatitis murine model.
    PLoS One. 2017;12:e0187551.
    PubMed     Abstract available

  656. RISALDE MA, Rivero-Juarez A, Romero-Palomo F, Frias M, et al
    Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar.
    PLoS One. 2017;12:e0186858.
    PubMed     Abstract available

  657. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    PubMed     Abstract available

  658. XIAO H, Shi M, Xie Y, Chi X, et al
    Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0186660.
    PubMed     Abstract available

  659. YINDOM LM, Mendy M, Bodimeade C, Chambion C, et al
    KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.
    PLoS One. 2017;12:e0188307.
    PubMed     Abstract available

  660. YANG A, Guo Z, Ren Q, Wu L, et al
    Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study.
    PLoS One. 2017;12:e0188190.
    PubMed     Abstract available

  661. SHIMIZU JF, Pereira CM, Bittar C, Batista MN, et al
    Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.
    PLoS One. 2017;12:e0187857.
    PubMed     Abstract available

  662. STROFFOLINI T, Sagnelli E, Andriulli A, Colloredo G, et al
    Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis.
    PLoS One. 2017;12:e0185710.
    PubMed     Abstract available

  663. GARRIGA C, Manzanares-Laya S, Garcia de Olalla P, Gorrindo P, et al
    Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.
    PLoS One. 2017;12:e0187893.
    PubMed     Abstract available

  664. CARLUCCI JG, Farooq SA, Sizemore L, Rickles M, et al
    Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers.
    PLoS One. 2017;12:e0188624.
    PubMed     Abstract available

  665. BRAGA ACS, Carneiro BM, Batista MN, Akinaga MM, et al
    Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity.
    PLoS One. 2017;12:e0188467.
    PubMed     Abstract available

  666. SPINA A, Lenglet A, Beversluis D, de Jong M, et al
    A large outbreak of Hepatitis E virus genotype 1 infection in an urban setting in Chad likely linked to household level transmission factors, 2016-2017.
    PLoS One. 2017;12:e0188240.
    PubMed     Abstract available

  667. LEE IC, Chau GY, Yeh YC, Chao Y, et al
    Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure.
    PLoS One. 2017;12:e0188552.
    PubMed     Abstract available

  668. LIM J, Kim K, Choi S, Park SM, et al
    The effectiveness and limitation of the national childhood hepatitis A vaccination program in the Republic of Korea: Findings from the Korean National Health and Nutrition Examination Survey (KNHANES), 2015.
    PLoS One. 2017;12:e0189210.
    PubMed     Abstract available

  669. MUNSHI SU, Tran TTT, Vo TNT, Tabassum S, et al
    Molecular characterization of hepatitis B virus in Bangladesh reveals a highly recombinant population.
    PLoS One. 2017;12:e0188944.
    PubMed     Abstract available

  670. CANGELOSI Q, Means SA, Ho H
    A multi-scale spatial model of hepatitis-B viral dynamics.
    PLoS One. 2017;12:e0188209.
    PubMed     Abstract available

  671. CANINI L, Imamura M, Kawakami Y, Uprichard SL, et al
    HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
    PLoS One. 2017;12:e0187409.
    PubMed     Abstract available

  672. SMITH JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, et al
    Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence.
    PLoS One. 2017;12:e0189255.
    PubMed     Abstract available

  673. COMSTOCK E, Kim CW, Murphy A, Emmanuel B, et al
    Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.
    PLoS One. 2017;12:e0188314.
    PubMed     Abstract available

  674. YIN F, Xie Y, Fan H, Zhang J, et al
    Mutations in hepatitis B virus polymerase are associated with the postoperative survival of hepatocellular carcinoma patients.
    PLoS One. 2017;12:e0189730.
    PubMed     Abstract available

  675. PANNETIER J, Gigonzac V, Lydie N, Desgrees du Lou A, et al
    Timing of chronic hepatitis B diagnosis after migration and its determinants among Sub-Saharan African migrants living in France.
    PLoS One. 2017;12:e0189196.
    PubMed     Abstract available

  676. DERESSA T, Damtie D, Fonseca K, Gao S, et al
    The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia.
    PLoS One. 2017;12:e0190149.
    PubMed     Abstract available

  677. BROQUETAS T, Garcia-Retortillo M, Hernandez JJ, Puigvehi M, et al
    Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.
    PLoS One. 2017;12:e0188303.
    PubMed     Abstract available

  678. LAY P, An S, Soeung S, Srey PS, et al
    Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes.
    PLoS One. 2017;12:e0185348.
    PubMed     Abstract available

    January 2016
  679. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    PubMed     Abstract available

  680. BOCHAROV G, Meyerhans A, Bessonov N, Trofimchuk S, et al
    Spatiotemporal Dynamics of Virus Infection Spreading in Tissues.
    PLoS One. 2016;11:e0168576.
    PubMed     Abstract available

  681. DE MIGUEL-DIEZ J, Lopez-de-Andres A, Jimenez-Garcia R, Puente-Maestu L, et al
    Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997-2012).
    PLoS One. 2016;11:e0166421.
    PubMed     Abstract available

  682. NJOKU OS, Manak MM, O'Connell RJ, Shutt AL, et al
    An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria.
    PLoS One. 2016;11:e0166711.
    PubMed     Abstract available

  683. LIMA K, de Souza Leal E, Cavalcanti AM, Salustiano DM, et al
    Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil.
    PLoS One. 2016;11:e0155854.
    PubMed     Abstract available

  684. BRUDER COSTA J, Dufeu-Duchesne T, Leroy V, Bertucci I, et al
    Pegylated Interferon alpha-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
    PLoS One. 2016;11:e0158297.
    PubMed     Abstract available

  685. PLAISTED WC, Zavala A, Hingco E, Tran H, et al
    Remyelination Is Correlated with Regulatory T Cell Induction Following Human Embryoid Body-Derived Neural Precursor Cell Transplantation in a Viral Model of Multiple Sclerosis.
    PLoS One. 2016;11:e0157620.
    PubMed     Abstract available

  686. FARSHADPOUR F, Taherkhani R, Tajbakhsh S, Gholizadeh Tangestani M, et al
    Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study.
    PLoS One. 2016;11:e0157615.
    PubMed     Abstract available

  687. WU H, Padhi A, Xu J, Gong X, et al
    Evidence for Within-Host Genetic Recombination among the Human Pegiviral Strains in HIV Infected Subjects.
    PLoS One. 2016;11:e0161880.
    PubMed     Abstract available

  688. O'DONNELL PE, Ye XZ, DeChellis MA, Davis VM, et al
    Lipodystrophy, Diabetes and Normal Serum Insulin in PPARgamma-Deficient Neonatal Mice.
    PLoS One. 2016;11:e0160636.
    PubMed     Abstract available

  689. REMIS RS, Liu J, Loutfy MR, Tharao W, et al
    Prevalence of Sexually Transmitted Viral and Bacterial Infections in HIV-Positive and HIV-Negative Men Who Have Sex with Men in Toronto.
    PLoS One. 2016;11:e0158090.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.